Abstract is: Expert Review of Anticancer Therapy is a monthly peer-reviewed medical journal covering all clinical aspects of cancer therapy. It was established in 2001 and is published by Taylor & Francis under the academic publishing division of Informa. The current Editor-in-Chief is Gertjan J L Kaspers who is Head of Pediatric Oncology at VU University Medical Center Amsterdam. According to Journal Citation Reports, the journal has a 2020 impact factor of 4.512 and a 2020 CiteScore of 6.4.
| medical journal | Q16024164 |
| peer review | Q215028 |
| scientific journal | Q5633421 |
| P6981 | ACNP journal ID | 2532655 |
| 2792712 | ||
| P1159 | CODEN | ERATBJ |
| P8375 | Crossref journal ID | 38060 |
| P1250 | Danish Bibliometric Research Indicator (BFI) SNO/CNO | 3008 |
| P1058 | ERA Journal ID | 16124 |
| P646 | Freebase ID | /m/0_x73gd |
| P8903 | HAL journal ID | 13218 |
| P1160 | ISO 4 abbreviation | Expert Rev. Anticancer Ther. |
| P236 | ISSN | 1473-7140 |
| 1744-8328 | ||
| P7363 | ISSN-L | 1473-7140 |
| P1277 | JUFO ID | 55977 |
| P9035 | Muck Rack media outlet ID | ExpertReviewofAnticancerTherapy |
| P1055 | NLM Unique ID | 101123358 |
| P243 | OCLC control number | 60638399 |
| P856 | official website | http://informahealthcare.com/journal/ery |
| http://www.future-drugs.com/loi/era | ||
| P10283 | OpenAlex ID | S93370067 |
| P3181 | OpenCitations bibliographic resource ID | 19133 |
| P7662 | Scilit journal ID | 478635 |
| P1156 | Scopus source ID | 21355 |
| P495 | country of origin | United Kingdom | Q145 |
| P1240 | Danish Bibliometric Research Indicator level | 1 | |
| P571 | inception | 2001-01-01 | |
| P8875 | indexed in bibliographic review | Science Citation Index Expanded | Q104047209 |
| Scopus | Q371467 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cancer | Q12078 |
| P123 | publisher | Informa | Q680946 |
| P1476 | title | Expert Review of Anticancer Therapy |
| Q85888795 | 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer |
| Q45887774 | 10th International Conference on Gene Therapy of Cancer. 13-15 December, 2001, Sidney Kimmel Cancer Center, San Diego, CA, USA. |
| Q51017898 | 10th International Symposium on Head And Neck Skin Cancer. |
| Q45872015 | 11th annual congress of the European Society of Gene Therapy |
| Q86704865 | 13 years of trabectedin, 5 years of Yondelis®: what have we learnt? |
| Q53232881 | 1st World Congress of the International Academy of Oral Oncology: oral cancer--a global challenge. |
| Q50698209 | 1st annual oncology update: advances and controversies. Steamboat Springs, Colorado, USA, 13-17 February 2001. |
| Q58876657 | 2010 Multidisciplinary Head and Neck Cancer Symposium |
| Q51159183 | 2010 Society for Neuro-Oncology Annual Meeting: a report of selected studies. |
| Q51145511 | 21st International Congress on Anticancer Treatment. |
| Q48414985 | 3-T ultrahigh-field intraoperative MRI for low-grade glioma resection. |
| Q53312954 | 4th international symposium on leukemia and lymphoma--molecular pharmacology and new treatment modalities. VU Medical Center, Amsterdam, The Netherlands, 7-10 March 2001. |
| Q84971451 | 5T4 as a target for immunotherapy in renal cell carcinoma |
| Q47583512 | 5th Canadian Melanoma Conference: research frontiers |
| Q53303336 | 5th International Congress of Nuclear Oncology and 15th National Congress of Turkish Society of Nuclear Medicine Kusadasi, Turkey, 1-5 May, 2002. |
| Q53270834 | 6th International Symposium and expert workshops on Leukemia and Lymphoma. 17-19 March, 2005, Amsterdam, The Netherlands. |
| Q83676709 | 6th Meeting of the European Society of Oncological Urology |
| Q50798112 | 7th annual International Conference on Ovarian Cancer. |
| Q79449948 | 7th meeting of the International Society of Geriatric Oncology. November 2-4, 2006, Kurhaus Hotel, Scheveningen, The Netherlands |
| Q38760623 | A catalogue of treatment and technologies for malignant pleural mesothelioma |
| Q91659275 | A comparison of magnetic resonance imaging techniques used to secure biopsies in prostate cancer patients |
| Q91799952 | A comprehensive review of protein kinase inhibitors for cancer therapy |
| Q37960916 | A debate on locoregional treatment of the primary tumor in patients presenting with stage IV breast cancer |
| Q57570685 | A decade of change in the treatment of advanced soft tissue sarcoma |
| Q79919775 | A fertile future? Life after cancer in young men |
| Q47731653 | A look at the progress of treating pancreatic cancer over the past 20 years |
| Q88693188 | A look at treatment strategies for relapsed multiple myeloma |
| Q37765591 | A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond |
| Q38101611 | A model for the regulation of T-type Ca(2+) channels in proliferation: roles in stem cells and cancer |
| Q98612573 | A multidisciplinary approach to soft-tissue sarcoma of the extremities |
| Q36636641 | A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy |
| Q47563055 | A new era for children with diffuse intrinsic pontine glioma: hope for cure? |
| Q38995416 | A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). |
| Q38760747 | A new look at the ALK gene in cancer: copy number gain and amplification |
| Q34625205 | A new understanding in the epidemiology of melanoma |
| Q100729807 | A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer |
| Q37866788 | A public-health perspective on screening colonoscopy |
| Q85761069 | A shared fight against cancer: the complementary roles of oncology physicians and oncology pharmacists |
| Q101141777 | A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials |
| Q38272867 | A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. |
| Q85737113 | A vaccine in renal cell carcinoma: are we nearing reality? |
| Q83159701 | AACR-NCI-EORTC International Conference 2009 |
| Q78380624 | ACCESS oncology and Zentaris sign product partnership |
| Q88078418 | ADAR1: a promising new biomarker for esophageal squamous cell carcinoma? |
| Q74450449 | AE-941 (Neovastat): a novel multifunctional antiangiogenic compound |
| Q74450489 | AEterna reports on its phase II trial of neovastat |
| Q37159523 | AKT pathway in neuroblastoma and its therapeutic implication |
| Q90699112 | ALK testing methods: is there a winner or loser? |
| Q38270016 | ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice? |
| Q99545260 | ASSOCIATION BETWEEN OBJECTIVE RESPONSE RATE AND OVERALL SURVIVAL IN METASTATIC NEUROENDOCRINE TUMORS TREATED WITH RADIOEMBOLIZATION: A SYSTEMATIC LITERATURE REVIEW AND REGRESSION ANALYSIS |
| Q37628710 | Abdominal wall desmoid tumors associated with pregnancy: current concepts |
| Q100546457 | Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer |
| Q96582049 | Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy |
| Q82847589 | Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer |
| Q37256808 | Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation |
| Q82623334 | Accelerated partial breast irradiation using TARGIT: the pros, cons and the need for long-term results |
| Q37732287 | Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. |
| Q38123201 | Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer |
| Q98773839 | Achieving Efficacious Immunotherapy for Patients with Glioblastoma |
| Q37945644 | Active immunotherapy for non-small-cell lung cancer: moving toward a reality |
| Q35576182 | Active specific immunotherapy for colorectal cancer |
| Q37614595 | Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications |
| Q37546041 | Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence? |
| Q37242682 | Addressing fertility needs of breast cancer patients: oncology perspective |
| Q87096448 | Addressing overtreatment following the diagnosis of localized prostate cancer |
| Q90655230 | Addressing the controversial role of ketogenic diets in cancer treatment |
| Q38451230 | Addressing the needs of colorectal cancer survivors: current strategies and future directions |
| Q80238657 | Adjuvant aromatase inhibitors and emerging quality-of-life considerations |
| Q38183890 | Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature |
| Q36334879 | Adjuvant chemotherapy for bladder cancer |
| Q38787215 | Adjuvant chemotherapy in elderly patients with breast cancer: key challenges |
| Q46602108 | Adjuvant temozolomide: how long and how much? |
| Q91974163 | Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate |
| Q57178071 | Adjuvant therapy for advanced renal cell carcinoma |
| Q57180783 | Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions |
| Q35918453 | Adjuvant therapy for malignant melanoma |
| Q83461345 | Adjuvant therapy for pancreas adenocarcinoma: where are we going? |
| Q52686461 | Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. |
| Q37965640 | Adjuvant therapy in colon cancer |
| Q48173221 | Adjuvant therapy in glioblastomas: false steps and real advances. |
| Q38123204 | Adjuvant therapy in node-positive vulvar cancer |
| Q43096597 | Adjuvant therapy of pancreatic cancer |
| Q39018742 | Adjuvant trastuzumab: a 10-year overview of its benefit. |
| Q59230887 | Adjuvant treatment for renal cell carcinoma: in the long run will we get the same answers? |
| Q38264782 | Adjuvant versus salvage radiotherapy following radical prostatectomy: do the AUA/ASTRO guidelines have all the answers? |
| Q36950499 | Adrenocortical carcinoma: role of laparoscopic surgery in treatment |
| Q35782912 | Adult T-cell leukemia: future prophylaxis and immunotherapy |
| Q36691805 | Adult human sarcomas. I. Basic science |
| Q36731430 | Adult human sarcomas. II. Medical oncology |
| Q35089127 | Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy |
| Q38624893 | Advanced dual-energy CT for head and neck cancer imaging. |
| Q28247449 | Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations |
| Q38162249 | Advanced kidney cancer: treating the elderly |
| Q39023478 | Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs |
| Q38153446 | Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives |
| Q35576200 | Advanced pancreatic cancer: is there a role for combination therapy? |
| Q43903120 | Advanced stage diagnosis of cancer: who is at greater risk? |
| Q89958600 | Advancements in predicting outcomes in patients with glioma: a surgical perspective |
| Q91465137 | Advancements in the clinical management of upper tract urothelial carcinoma |
| Q38062019 | Advances and perspectives in lung cancer imaging using multidetector row computed tomography |
| Q45236675 | Advances and trends in dermato-oncology |
| Q38153443 | Advances in biomarkers for esophageal cancer |
| Q37656206 | Advances in breast cancer treatment: the emerging role of ixabepilone |
| Q30978011 | Advances in combined radiation therapy for the management of rectal cancer |
| Q36974722 | Advances in dendritic-cell-based therapeutic vaccines for cervical cancer |
| Q34969208 | Advances in diagnosis and management of oligodendroglioma |
| Q34734203 | Advances in diagnosis and therapy of neuroendocrine tumors |
| Q37774357 | Advances in fertility-sparing surgery for cervical cancer |
| Q35987770 | Advances in immune-based therapies of renal cell carcinoma |
| Q35987762 | Advances in intravesical therapy of urinary bladder cancer |
| Q38190106 | Advances in mechanisms of resistance to aromatase inhibitors |
| Q37038918 | Advances in minimally invasive surgery in the treatment of colorectal cancer |
| Q55467156 | Advances in neuro-oncology: novel therapies and clinical trials. |
| Q35204975 | Advances in prophylactic cancer vaccine research |
| Q37134458 | Advances in radiation therapy of head and neck cancer |
| Q34733937 | Advances in systemic therapy of small cell cancer of the lung |
| Q35160190 | Advances in targeted therapy for chronic myeloid leukemia. |
| Q34533253 | Advances in the adjuvant treatment of infantile fibrosarcoma |
| Q57305672 | Advances in the evaluation and management of lymph node involvement in urothelial carcinoma of the bladder |
| Q38068205 | Advances in the management of melanoma: targeted therapy, immunotherapy and future directions |
| Q34734301 | Advances in the management of patients with non-Hodgkin's lymphoma |
| Q35843721 | Advances in the management of testicular cancer |
| Q35034828 | Advances in the staging of renal cell carcinoma |
| Q92907759 | Advances in the therapy of BRAFV600E metastatic colorectal cancer |
| Q36407437 | Advances in the treatment of Waldenström's macroglobulinemia |
| Q38731174 | Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer |
| Q91218728 | Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors |
| Q91516755 | Adverse effects of chemotherapy and their management in Pediatric patients with Non-Hodgkin's Lymphoma in Kenya: A descriptive, situation analysis study |
| Q34194088 | Aerobic glycolysis: a novel target in kidney cancer |
| Q38270627 | Afatinib and lung cancer. |
| Q38612204 | Agents in the preclinical development stage for non-small cell lung cancer |
| Q60469437 | Aging: an important risk factor in chemotherapy-associated vascular diseases |
| Q35987731 | Aldesleukin in advanced renal cell carcinoma |
| Q81501644 | Alemtuzumab |
| Q33380135 | Alemtuzumab for B-cell chronic lymphocytic leukemia |
| Q37134417 | Alemtuzumab in the treatment of chronic lymphocytic lymphoma |
| Q38055497 | All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. |
| Q36636648 | Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma |
| Q58049115 | Allogeneic stem cell transplantation for renal cell carcinoma |
| Q130073510 | Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma |
| Q34319010 | Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers |
| Q48542926 | American Radium Society 92nd Annual Meeting |
| Q85021558 | American Society of Clinical Oncology 2010 colorectal update |
| Q42909159 | American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section |
| Q48840371 | American Society of Clinical Oncology 2011 CNS tumors update |
| Q54200515 | American society of clinical oncology 2002. Orlando, Florida, USA, 18-22 May, 2002. |
| Q48271318 | Amino acid PET in neuro-oncology: applications in the clinic |
| Q40049030 | An analysis of clinical characteristics and patient outcomes in primary mediastinal sarcomas |
| Q36605358 | An approach to the evaluation and treatment of Cushing's disease |
| Q92496193 | An aspirin a day keeps ovarian cancer at bay? |
| Q90580035 | An evidence-based analysis of the management of N0 neck in patients with cancer of the parotid gland |
| Q36352068 | An overview of uterine cancer and its management |
| Q92612495 | An update on advanced dual-energy CT for head and neck cancer imaging |
| Q92961348 | An update on current and future treatment options for chondrosarcoma |
| Q93006641 | An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer |
| Q38068207 | An update on pegylated IFN-α2b for the adjuvant treatment of melanoma |
| Q52683184 | An update on radiation therapy in head and neck cancers. |
| Q92427230 | An update on synthetic high-density lipoprotein-like nanoparticles for cancer therapy |
| Q37357291 | Anagrelide: 20 years later |
| Q34549542 | Anagrelide: an update on its mechanisms of action and therapeutic potential |
| Q37952236 | Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. |
| Q38872183 | Anaplastic lymphoma kinase inhibitors in elderly patients with advanced non-small cell lung cancer |
| Q38096472 | Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment? |
| Q37411178 | Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy |
| Q37854708 | Anaplastic thyroid cancer: a comprehensive review of novel therapy |
| Q35034811 | Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen |
| Q36500527 | Anastrozole for breast cancer: recent advances and ongoing challenges |
| Q34733910 | Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer |
| Q85718317 | Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice |
| Q38768462 | Anatomical templates of lymph node dissection for upper tract urothelial carcinoma: a systematic review of the literature |
| Q37256846 | Androgen receptor: role and novel therapeutic prospects in prostate cancer |
| Q37628695 | Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies |
| Q39259089 | Angiogenesis inhibitors in tackling recurrent glioblastoma |
| Q36235571 | Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy. |
| Q38186064 | Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies |
| Q35160210 | Angiogenic tumor markers, antiangiogenic agents and radiation therapy |
| Q37782099 | Animal models of osteosarcoma |
| Q91953616 | Anti-BCMA antibodies in the future management of multiple myeloma |
| Q37256836 | Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? |
| Q85096401 | Anti-EGFR therapy in first-line colorectal cancer |
| Q47554435 | Anti-GD2 immunotherapy for neuroblastoma. |
| Q39007525 | Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. |
| Q36636633 | Anti-VEGF therapy: a new approach to colorectal cancer therapy |
| Q38194159 | Anti-angiogenic agent ramucirumab: meaningful or marginal? |
| Q34734053 | AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients |
| Q38153445 | Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective |
| Q38128896 | Antiangiogenic approach in soft-tissue sarcomas. |
| Q36235557 | Antiangiogenic strategies in hepatocellular carcinoma: current status |
| Q38010802 | Antiangiogenic therapies in glioblastoma multiforme |
| Q45820306 | Antiangiogenic therapies: is VEGF-A inhibition alone enough? |
| Q51709880 | Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. |
| Q35070445 | Antibody-based therapeutics in oncology |
| Q34577226 | Antibody-directed enzyme prodrug therapy (ADEPT) for cancer |
| Q35987788 | Anticancer drug development based on modulation of the Bcl-2 family core apoptosis mechanism |
| Q34734079 | Anticancer drugs that induce cancer-associated cachectic syndromes |
| Q37845836 | Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. |
| Q89568332 | Anticancer therapy and lung injury: molecular mechanisms |
| Q38679872 | Anticancer treatments and female fertility: clinical concerns and role of oncologists in oncofertility practice |
| Q74450698 | Anticoagulants in thrombosis and cancer: the missing link |
| Q38132247 | Antineoplastic therapy-induced pulmonary toxicity. |
| Q35611906 | Antioxidants in cancer care: when and how to use them as an adjunct to standard and experimental therapies |
| Q36334885 | Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects |
| Q36817119 | Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients |
| Q73841217 | Antitumor benefits from two antiangiogenesis agents |
| Q35611859 | Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells |
| Q34022431 | Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases |
| Q57106877 | Apalutamide for the treatment of prostate cancer |
| Q73334874 | Aplidin increases sensitivity to treatment in leukemia and lymphoma cells |
| Q38598277 | Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery? |
| Q37909356 | Applications of diffusion-weighted magnetic resonance imaging in renal cell carcinoma. |
| Q51825453 | Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. |
| Q37483966 | Applications of neural and mesenchymal stem cells in the treatment of gliomas |
| Q100950441 | Applying adjuvant therapy for melanoma into clinical practice |
| Q35918427 | Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting |
| Q35117738 | Aromatase inhibitors for treatment of postmenopausal patients with breast cancer |
| Q34734521 | Aromatase inhibitors in breast cancer therapy |
| Q74450491 | Aronex Pharmaceuticals reports on annamycin phase I trial |
| Q84962646 | Arsenic trioxide in acute promyelocytic leukemia: potion not poison |
| Q90727213 | Asbestos-related cancers: the 'Hidden Killer' remains a global threat |
| Q85515674 | Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance |
| Q38265114 | Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. |
| Q57903787 | Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials |
| Q37316991 | Association between response to primary treatments and MGMT status in glioblastoma |
| Q53128219 | At the crossroads of molecular biology, pathology and the clinic. |
| Q89751174 | Atezolizumab for the treatment of breast cancer |
| Q74450353 | Atrasentan demonstrates survival benefit in hormone-refractory prostate cancer |
| Q36185608 | Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer |
| Q30249199 | Atypical epithelial hyperplasia of the breast: state of the art. |
| Q38222665 | Atypical fibroxanthoma: new insights |
| Q36284530 | Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges |
| Q36352091 | Aurora A and B kinases as targets for cancer: will they be selective for tumors? |
| Q80955247 | Authentication of cell lines: ignore at your peril! |
| Q37086003 | Autocrine motility factor receptor: a clinical review |
| Q35160186 | Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphoma |
| Q36284506 | Autologous hematopoietic stem cell transplantation for pediatric solid tumors |
| Q27023375 | Autophagy and endocrine resistance in breast cancer |
| Q91954552 | Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy |
| Q52655736 | Avelumab for the treatment of urothelial cancer. |
| Q52684760 | Avelumab: a new standard for treating metastatic Merkel cell carcinoma. |
| Q89231103 | Avelumab: is it time to get excited? |
| Q38195331 | Axillary reverse lymphatic mapping in breast cancer surgery: a comprehensive review |
| Q38439661 | Axitinib in metastatic renal cell carcinoma |
| Q37546018 | Azacitidine for the treatment of myelodysplastic syndrome |
| Q48840378 | BDNF/TrkB signaling as an anti-tumor target |
| Q74450326 | BMS and Exelixis target tumor suppression pathways |
| Q36381270 | BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance |
| Q39006844 | Basis for molecular diagnostics and immunotherapy for esophageal cancer. |
| Q37788236 | Bendamustine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma |
| Q37385371 | Bendamustine in the treatment of chronic lymphocytic leukemia |
| Q37687378 | Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls |
| Q36352060 | Benefits of laparoscopic prostate-sparing radical cystectomy |
| Q37982447 | Benign and malignant apocrine lesions of the breast. |
| Q74450486 | Berlex Laboratories to market new treatment for B-CLL |
| Q37577915 | Better treatment for breast cancer in older patients |
| Q33640753 | Bevacizumab and breast cancer: current therapeutic progress and future perspectives |
| Q37159492 | Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer. |
| Q38081238 | Bevacizumab as front-line treatment for newly diagnosed epithelial cancer |
| Q37159495 | Bevacizumab for the treatment of advanced non-small-cell lung cancer |
| Q38056748 | Bevacizumab in colorectal cancer: current and future directions |
| Q38058530 | Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial |
| Q38617495 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer |
| Q37965628 | Bevacizumab in glioblastoma multiforme. |
| Q38386873 | Bevacizumab in high-grade gliomas: past, present, and future |
| Q37931886 | Bevacizumab in non-small-cell lung cancer: a review |
| Q36788459 | Bevacizumab in the management of solid tumors |
| Q37299995 | Bevacizumab in the treatment of breast cancer |
| Q81458262 | Bevacizumab in the treatment of ovarian cancer |
| Q38068203 | Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date |
| Q37299992 | Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma |
| Q38010797 | Bevacizumab: overview of the literature |
| Q35728639 | Bexarotene: a clinical review |
| Q91400916 | Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer |
| Q38765001 | Beyond platinum treatment for NSCLC: what does the future hold? |
| Q37782088 | Beyond triple-negative breast cancer: the need to define new subtypes |
| Q34293191 | Bicalutamide (Casodex) in the treatment of prostate cancer |
| Q37546050 | Bilateral Wilms' tumor: the need to improve outcomes |
| Q38636033 | Binimetinib for the treatment of NRAS-mutant melanoma. |
| Q48348035 | Biography: Dr Iain Frame, director of research, prostate cancer UK. |
| Q37242685 | Biologic therapies for advanced pancreatic cancer |
| Q38062018 | Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies |
| Q60637528 | Biological agents in head and neck cancer |
| Q37788248 | Biological considerations and clinical applications of new HER2-targeted agents |
| Q37546065 | Biological mechanisms of bevacizumab-associated adverse events |
| Q34167249 | Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy |
| Q34677457 | Biology and management of clear cell sarcoma: state of the art and future perspectives |
| Q37687382 | Biology and management of inflammatory breast cancer |
| Q36731414 | Biology and treatment of ductal carcinoma in situ |
| Q38156192 | Biology in prevention and treatment of brain metastases |
| Q37300035 | Biology of testicular germ cell tumors. |
| Q37256811 | Biomarker panel diagnosis of thyroid cancer: a critical review |
| Q38217738 | Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer |
| Q38575013 | Biomarkers and novel agents in esophago-gastric cancer: are we making progress? |
| Q38242279 | Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer. |
| Q37656233 | Biomarkers for prostate cancer detection |
| Q37025951 | Biomarkers in clear cell renal cell carcinoma |
| Q38256309 | Biopsy sampling and histopathological markers for diagnosis of prostate cancer. |
| Q38394272 | Biosimilar monoclonal antibodies in lymphoma: a critical appraisal |
| Q36118409 | Bisphosphonates and bone metastases: current status and future directions |
| Q37038905 | Bladder cancer following upper tract urothelial carcinoma |
| Q36334889 | Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets |
| Q87403374 | Bladder conservation for muscle-invasive bladder cancer |
| Q33915293 | Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? |
| Q90023855 | Bladder-sparing treatment options in localized muscle-invasive bladder cancer |
| Q87096125 | Blinatumomab in acute lymphoblastic leukemia |
| Q38838419 | Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients? |
| Q35728630 | Bortezomib and its role in the management of patients with multiple myeloma |
| Q37202761 | Bortezomib in the front-line treatment of multiple myeloma |
| Q54349085 | Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. |
| Q37952245 | Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas |
| Q91515445 | Brain metastases and treatment: multiplying cognitive toxicities |
| Q48569495 | Brain metastases from non-small-cell lung cancer: is there room for improvement? |
| Q38168924 | Brain metastases in breast cancer |
| Q35728733 | Brain metastases in lung cancer |
| Q102070483 | Brain metastases in metastatic cancer: a review of recent advances in systemic therapies |
| Q81722085 | Brain metastases of breast cancer |
| Q37004670 | Brain metastasis from non-seminomatous germ cell tumor of the testis |
| Q84419818 | Branched peptides as novel tumor-targeting agents for bladder cancer |
| Q38584383 | Breast cancer and immunology: biomarker and therapeutic developments |
| Q82781695 | Breast cancer cell dormancy in bone marrow: potential therapeutic targets within the marrow microenvironment |
| Q57134756 | Breast cancer chemoprevention |
| Q36653524 | Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade |
| Q38048815 | Breast cancer intratumor genetic heterogeneity: causes and implications |
| Q36613998 | Breast cancer metastasis progression as revealed by intravital videomicroscopy |
| Q38081240 | Breast cancer risk after exposure to fertility drugs |
| Q36573827 | Breast cancer susceptibility testing: past, present and future. |
| Q84451530 | Breast cancer, obesity and hormonal imbalance: a worrisome trend |
| Q35204980 | Breast cancer: occurrence, risk factors and hormone metabolism |
| Q51166159 | Breast care in 2011 and beyond: state of policy, state of science. |
| Q38081241 | Breast irradiation and lactation: a review |
| Q46425527 | Breath testing as a method for detecting lung cancer |
| Q87170636 | Breath testing as a method for detecting lung cancer |
| Q74450396 | British Biotech and MethylGene sign agreement on Phase II antisense drug |
| Q37809860 | Burden of metastatic bone disease from genitourinary malignancies |
| Q104561165 | Burnout in medical oncology during the COVID-19 pandemic |
| Q34734092 | CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond |
| Q52658445 | CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing? |
| Q102377004 | CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis |
| Q37004668 | CNS metastasis in primary breast cancer |
| Q96436749 | COVID-19: how will this impact children with cancer, now and in the future? |
| Q35843673 | COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer |
| Q37732278 | CT and MRI of hepatocellular carcinoma: an update |
| Q38055492 | Cabazitaxel in metastatic castration-resistant prostate cancer |
| Q90648721 | Cabozantinib for the treatment of hepatocellular carcinoma |
| Q38668871 | Cabozantinib for the treatment of kidney cancer |
| Q92593149 | Cadmium: a new risk factor for endometrial cancer? |
| Q34734502 | Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer |
| Q90361113 | Can CDK4/6 inhibitors cause fatal lung injury? |
| Q34734262 | Can cure be achieved in patients with head and neck carcinomas? The problem of second neoplasm |
| Q36284499 | Can diet prevent nonmelanoma skin cancer progression? |
| Q53338088 | Can miRNA profiling allow us to determine which patients with esophageal cancer will respond to chemoradiotherapy? |
| Q84419561 | Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance? |
| Q37765583 | Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma? |
| Q57316222 | Cancer 2025: Assessing cancer risk |
| Q64018988 | Cancer 2025: Diagnosis |
| Q57487569 | Cancer 2025: Radiotherapy |
| Q80273856 | Cancer 2025: conclusion |
| Q80273823 | Cancer 2025: introduction |
| Q35508820 | Cancer and the microbiome: potential applications as new tumor biomarker |
| Q93332411 | Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors |
| Q44263078 | Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction |
| Q38786054 | Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. |
| Q36448691 | Cancer of the esophagus: the value of preoperative patient assessment. |
| Q35782929 | Cancer of the nasal cavity and paranasal sinuses |
| Q37004676 | Cancer stem cells and brain tumors: uprooting the bad seeds. |
| Q51775290 | Cancer stem cells and the cell cycle: targeting the drive behind breast cancer. |
| Q79251840 | Cancer therapies crisis in the USA |
| Q35786517 | Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. |
| Q53114191 | Cancer therapy: could a novel test predict the amount of drug that reaches its target? |
| Q47648903 | Cancer vaccines: will we ever learn? |
| Q35160222 | Cancer-related cachexia and oxidative stress: beyond current therapeutic options |
| Q34236005 | Capecitabine in gastric cancer |
| Q39170865 | Capecitabine in locally advanced anal cancer, do we need randomised evidence? |
| Q44060826 | Capecitabine in the management of colorectal cancer. |
| Q80445005 | Capecitabine in the treatment of colorectal cancer |
| Q37085987 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. |
| Q36613965 | Capecitabine-docetaxel combination treatment |
| Q35987726 | Capecitabine: the new generation of fluoropyrimidines in colorectal cancer |
| Q92335523 | Capmatinib for the treatment of non-small cell lung cancer |
| Q34571555 | Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs |
| Q37025960 | Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. |
| Q48205375 | Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study |
| Q37118932 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies |
| Q74450310 | Carotenoids identify lung cancer risk |
| Q83903351 | Caspase 9b: a new target for therapy in non-small-cell lung cancer |
| Q50270201 | Castration-naive metastatic prostate cancer: reshaping old paradigms |
| Q85737108 | Cause-effect? Understanding the risk factors associated with bladder cancer |
| Q36731417 | Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy |
| Q45107156 | Celecoxib: a novel treatment for lung cancer |
| Q74450358 | Cell Genesys reports long-term survival data in Phase II trial of GVAX |
| Q78721300 | Cell fusion technology vaccine tested in kidney cancer clinical trial |
| Q35611888 | Cell-based immune therapy for metastatic renal cancer |
| Q73334868 | Celsion microwave therapy proves effective in breast cancer |
| Q38816270 | Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance |
| Q38205470 | Central nervous system toxicities of chemotherapeutic agents |
| Q37546027 | Cervical cancer therapy: current, future and anti-angiogensis targeted treatment |
| Q38010796 | Cetuximab in metastatic colorectal cancer. |
| Q43261590 | Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial |
| Q55013304 | Cetuximab in non-small-cell lung cancer |
| Q36668224 | Cetuximab in the treatment of head and neck cancer |
| Q37866779 | Cetuximab in the treatment of squamous cell carcinoma of the head and neck |
| Q46750806 | Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial |
| Q36788445 | Cetuximab plus irinotecan in refractory colorectal cancer patients |
| Q37118923 | Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer |
| Q37242667 | Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. |
| Q88606527 | Challenges and concerns of persistent opioid use in cancer patients |
| Q35641231 | Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment |
| Q38222270 | Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer |
| Q38484668 | Challenges in the diagnosis and management of cervical neuroendocrine carcinoma |
| Q37799830 | Challenges of drug resistance in the management of pancreatic cancer |
| Q46627034 | Challenging a dogma: five-year survival does not equal cure in all colorectal cancer patients |
| Q34734197 | Changing boundaries in the treatment of malignant gliomas. |
| Q36605363 | Changing paradigms in the surgical and medical management of acromegaly |
| Q103009579 | Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives |
| Q38672084 | Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy |
| Q36752040 | Chemokines and squamous cancer of the head and neck: targets for therapeutic intervention? |
| Q30435873 | Chemokines as therapeutic targets in renal cell carcinoma |
| Q80955303 | Chemoprevention of breast cancer |
| Q39016806 | Chemoprevention of colorectal cancer in inflammatory bowel disease |
| Q36185641 | Chemoprevention of lung cancer: concepts and strategies |
| Q35070438 | Chemoprevention of lung cancer: soon daily practice? |
| Q73334884 | Chemoprevention of prostate cancer |
| Q64931648 | Chemoprevention of prostate cancer: breakthroughs and controversies |
| Q75195182 | Chemoprevention of superficial bladder cancer |
| Q34969274 | Chemoprotective potential of phase 2 enzyme inducers |
| Q34734122 | Chemoradiation in cervical carcinoma: a must? |
| Q80129553 | Chemoradiation in locally advanced head and neck cancer: new evidence, new challenges |
| Q35089131 | Chemoradiotherapy of non-small cell lung cancer |
| Q34691622 | Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx cancer |
| Q80273844 | Chemotherapy |
| Q37854714 | Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. |
| Q38010806 | Chemotherapy and targeted agents for thymic malignancies |
| Q38594531 | Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options |
| Q36788478 | Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future |
| Q36499252 | Chemotherapy for elderly patients with advanced colorectal carcinoma |
| Q37614566 | Chemotherapy for lung cancer: the state of the art in 2009. |
| Q36352095 | Chemotherapy for metastatic melanoma |
| Q34969177 | Chemotherapy for the treatment of metastatic brain tumors |
| Q73027787 | Chemotherapy for trophoblastic disease: current standards |
| Q36499238 | Chemotherapy in the treatment of malignant gliomas |
| Q36636656 | Chemotherapy practices and perspectives in invasive bladder cancer |
| Q38081243 | Chemotherapy regimens in early breast cancer: major controversies and future outlook |
| Q36532115 | Chemotherapy resistance in osteosarcoma: current challenges and future directions. |
| Q37732281 | Chemotherapy-associated hepatotoxicity: how concerned should we be? |
| Q47803255 | Chemotherapy-induced neutropenia and the prognosis of colorectal cancer: a meta-analysis of cohort studies |
| Q47629566 | Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens |
| Q50984719 | Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies. |
| Q98215237 | Cholangiocarcinoma: investigations into pathway-targeted therapies |
| Q35124844 | Choosing first-line therapy for chronic lymphocytic leukemia. |
| Q38170453 | Choosing treatment options for patients with relapsed/refractory multiple myeloma |
| Q34560909 | Chronic lymphocytic leukemia: planning for an aging population |
| Q93155465 | Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism? |
| Q57283781 | Circulating long non-coding RNAs: could they be a useful tool for cancer therapy monitoring? |
| Q37982454 | Circulating microRNAs in cancer: diagnostic and prognostic significance |
| Q37687372 | Circulating tumor cells as prognostic marker in metastatic breast cancer |
| Q46119616 | Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? |
| Q37134422 | Cladribine in indolent non-Hodgkin's lymphoma |
| Q35918435 | Cladribine: from the bench to the bedside--focus on hairy cell leukemia |
| Q38069185 | Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents? |
| Q38399838 | Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy. |
| Q38169227 | Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy |
| Q84568926 | Clinical and biological diversity of splenic marginal zone lymphoma |
| Q35641216 | Clinical and epidemiologic burden of chronic myelogenous leukemia |
| Q36879168 | Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer |
| Q37752394 | Clinical applications of PET and PET/CT in pediatric malignancies |
| Q37845828 | Clinical applications of positron emission tomography in sarcoma management. |
| Q34734002 | Clinical applications of radioprotectors |
| Q48517239 | Clinical challenges in de novo pediatric acute myeloid leukemia |
| Q38630561 | Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. |
| Q37598932 | Clinical efficacy and safety of zoledronic acid in prostate and breast cancer |
| Q85096405 | Clinical efficacy of cytoreductive surgery and hyperthermic chemotherapy in peritoneal carcinomatosis from gastric cancer |
| Q55463103 | Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe? |
| Q36448668 | Clinical experiences with G17DT in gastrointestinal malignancies |
| Q38263563 | Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. |
| Q38176985 | Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma |
| Q104285654 | Clinical implications of lung neuroendocrine neoplasm classification |
| Q37774358 | Clinical management of borderline ovarian tumors |
| Q35918445 | Clinical management of medulloblastoma in adults |
| Q100748543 | Clinical management of squamous cell carcinoma of the tongue: patients not eligible for free flaps, a systematic review of the literature |
| Q37821898 | Clinical management of uterine papillary serous carcinoma |
| Q36500533 | Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer |
| Q42860433 | Clinical practice and the tobacco epidemic: relevance of a global public health problem in the clinical setting |
| Q36334870 | Clinical practice guidelines on antiemetics in oncology. |
| Q38153774 | Clinical practice-changing trials: the HERA study paradigm. |
| Q100546312 | Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies |
| Q38055499 | Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas |
| Q36448683 | Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. |
| Q38153777 | Clinical trials of viral therapy for malignant gliomas |
| Q36235551 | Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines |
| Q39098904 | Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow |
| Q37598938 | Clinicopathologic and molecular disease prognostication for papillary thyroid cancer. |
| Q36118379 | Clodronate in the prevention and treatment of skeletal metastasis |
| Q36731404 | Clofarabine for the treatment of acute lymphoblastic leukemia |
| Q36407434 | Cloretazine for the treatment of acute myeloid leukemia |
| Q37752361 | Closing in on the pathogenesis of the 5q- syndrome |
| Q37931900 | Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors |
| Q38010804 | Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review. |
| Q37242687 | Colon and rectal cancer after renal transplantation |
| Q57785517 | Colon capsule endoscopy and its effectiveness in the diagnosis and management of colorectal neoplastic lesions |
| Q38186139 | Colorectal and anal cancer in HIV/AIDS patients: a comprehensive review |
| Q38002471 | Colorectal cancer and thoracic surgeons: close encounters of the third kind |
| Q35782915 | Colorectal cancer as a complex disease: defining at-risk subjects in the general population - a preventive strategy |
| Q37799822 | Colorectal cancer chemoprevention: the potential of a selective approach |
| Q38195328 | Colorectal cancer in inflammatory bowel disease: a shift in risk? |
| Q34656802 | Colorectal cancer stem cells and their implications for novel anticancer therapy |
| Q35611894 | Colorectal cancer: screening and surveillance for high-risk individuals |
| Q53482447 | Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations. |
| Q34734518 | Combination chemotherapy for metastatic breast cancer |
| Q35843682 | Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. |
| Q37614572 | Combination of radiotherapy and chemotherapy in locally advanced NSCLC. |
| Q37546023 | Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma |
| Q54978694 | Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. |
| Q37316986 | Combination therapy for malignant glioma based on PTEN status |
| Q45378019 | Combination therapy for older men with colorectal cancer: are two drugs better than one? |
| Q98214824 | Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors |
| Q57180782 | Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies |
| Q37316980 | Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease |
| Q35611872 | Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer |
| Q48867952 | Combined chemotherapy and intensity-modulated radiotherapy for the treatment of head and neck cancers |
| Q37008868 | Combined modalities approach for localized adult extremity soft-tissue sarcoma |
| Q36752037 | Combined modality treatment of laryngeal squamous cell carcinoma |
| Q49833624 | Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer |
| Q84942416 | Combining MRI with mammography: a more effective approach to breast cancer detection |
| Q37866791 | Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. |
| Q36381303 | Combining surgery and chemotherapy for invasive bladder cancer: current and future directions |
| Q37845834 | Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of age. |
| Q52656386 | Comparison of the effects of local treatment strategies in non-metastatic Ewing sarcoma of bone. |
| Q50938405 | Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. |
| Q38123203 | Complications of prostate biopsy |
| Q35782958 | Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience |
| Q35843699 | Computerized tomography colonography |
| Q38139996 | Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. |
| Q37411168 | Concurrent chemotherapy and radiotherapy for head and neck cancer |
| Q129755106 | Considerations regarding maintenance therapy for acute myeloid leukemia in remission |
| Q45007456 | Contemplating bladder cancer care: can we cut costs and improve quality of care? |
| Q37821895 | Contemporary management of localized penile cancer |
| Q36389716 | Contemporary management of muscle-invasive bladder cancer |
| Q37411175 | Contemporary management of papillary carcinoma of the thyroid gland |
| Q37774353 | Contemporary treatment of high-risk localized prostate cancer |
| Q23922906 | Contralateral prophylactic mastectomy for patients with unilateral breast cancer |
| Q89797153 | Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients |
| Q87285910 | Contralateral prophylactic mastectomy: are we overtreating patients? |
| Q35089134 | Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer |
| Q36573859 | Controversial issues and optimal management of stage T1G3 bladder cancer |
| Q37788242 | Controversies and challenges in the current management of nasopharyngeal cancer |
| Q93195800 | Controversies in locoregional management of breast cancer with low volume pN0(i+) and pN1mi nodal disease |
| Q95821232 | Controversies in radiotherapy for pediatric Hodgkin's lymphoma |
| Q38176433 | Controversies in the management of stage III non-small-cell lung cancer |
| Q37338248 | Controversies in the management of stage IIIA non-small-cell lung cancer |
| Q34969223 | Controversies in the therapy of low-grade glioma: when and how to treat |
| Q37118950 | Controversies over the role of radiation therapy for ductal carcinoma in situ |
| Q81900242 | Controversies surrounding the use of neoadjuvant chemotherapy in locally advanced head and neck cancer |
| Q37030814 | Convection-enhanced delivery for treatment of brain tumors |
| Q94546108 | Correction |
| Q48769026 | Correction to: Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma |
| Q89840631 | Corrigendum |
| Q95359732 | Corrigendum |
| Q95523124 | Corrigendum |
| Q36381274 | Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan |
| Q45937975 | Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma? |
| Q38228823 | Could valproic acid be an effective anticancer agent? The evidence so far. |
| Q38055495 | Craniofacial resection and its role in the management of sinonasal malignancies |
| Q36605386 | Craniopharyngiomas: an update |
| Q78721313 | Cream to be tested as skin cancer care |
| Q33184877 | Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma |
| Q39173261 | Critical decision-making in radiotherapy for early stage breast cancer in a neo-adjuvant treatment era. |
| Q73841213 | Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma |
| Q37982440 | Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer |
| Q35160229 | Cryotherapy for prostate cancer |
| Q80145422 | Curability of lung cancer |
| Q38640531 | Curative therapies for hepatocellular carcinoma: an update and perspectives |
| Q101453772 | Curative therapy for rectal cancer |
| Q37809861 | Current and emerging molecular targets in glioma |
| Q38096475 | Current and emerging surveillance strategies to expand the window of opportunity for curative treatment after surgery in colorectal cancer |
| Q102328780 | Current and emerging therapies for localized high-risk prostate cancer |
| Q38030595 | Current and emerging treatments in the management of castration-resistant prostate cancer |
| Q47781457 | Current and future immunotherapies for thyroid cancer |
| Q38194585 | Current and future management of Ph/BCR-ABL positive ALL. |
| Q36352079 | Current and future status of prostate cancer chemoprevention |
| Q47360357 | Current and future therapeutic approaches for osteosarcoma. |
| Q57163699 | Current and future therapeutic approaches for the treatment of follicular lymphoma |
| Q52653783 | Current and future therapeutic approaches for the treatment of small cell lung cancer. |
| Q57129470 | Current and future therapies for targeting HER2 mutations in gastrointestinal cancer |
| Q49847154 | Current approaches for identifying high-risk non-muscle invasive bladder cancer |
| Q34734115 | Current approaches of neoadjuvant chemotherapy in cervical cancer |
| Q52633086 | Current approaches to challenging scenarios in myeloproliferative neoplasms. |
| Q79896739 | Current challenges in cancer pain management: does the WHO ladder approach still have relevance? |
| Q48221094 | Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. |
| Q38608627 | Current challenges of lung cancer care in an aging population |
| Q36118405 | Current chemotherapeutic strategies for rhabdomyosarcoma |
| Q100297074 | Current clinical management of elderly patients with glioma |
| Q35843690 | Current clinical management of gastrointestinal stromal tumors |
| Q92500317 | Current clinical management of primary cardiac sarcoma |
| Q37577928 | Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. |
| Q38162288 | Current concepts and future strategies in the management of intracranial germinoma |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q36731422 | Current concepts in multimodality therapy for retroperitoneal sarcoma |
| Q35034835 | Current concepts in the treatment of Ewing's sarcoma |
| Q37242673 | Current concepts on the surgical and medical management of osteosarcoma. |
| Q84721720 | Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer |
| Q99619570 | Current developments in the combination therapy of relapsed/refractory multiple myeloma |
| Q37628704 | Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme |
| Q30703391 | Current epidemiological trends and surveillance issues in brain tumors |
| Q38183895 | Current indications and results of orthotopic ileal neobladder for bladder cancer. |
| Q34969240 | Current management and prognostic factors for adult ependymoma |
| Q38176387 | Current management options for liposarcoma and challenges for the future |
| Q38241395 | Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. |
| Q38101612 | Current opinion on optimal treatment for colorectal cancer. |
| Q37038897 | Current optimal chemotherapy for advanced urothelial cancer |
| Q38020247 | Current progress in using vitamin D and its analogs for cancer prevention and treatment |
| Q39422853 | Current questions in soft tissue sarcoma: further steps with Yondelis®. |
| Q93159086 | Current radiotherapy techniques in NSCLC: challenges and potential solutions |
| Q52687951 | Current research into novel therapeutic vaccines against cervical cancer. |
| Q37931895 | Current role and safety profile of aromatase inhibitors in early breast cancer |
| Q26991953 | Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma |
| Q38317384 | Current role of cabozantinib in metastatic castration-resistant prostate cancer |
| Q36235561 | Current role of image-guided ablative therapies in lung cancer. |
| Q37508016 | Current role, techniques and outcomes of percutaneous biopsy of renal tumors |
| Q36235576 | Current stage-specific chemotherapeutic options in colon cancer |
| Q39499604 | Current standards and future directions for prostate cancer radiation therapy |
| Q35987752 | Current state of immunotherapy for bladder cancer |
| Q36879150 | Current state of screening for bladder cancer |
| Q38633227 | Current status and future perspectives of fluorescence-guided surgery for cancer |
| Q37894673 | Current status of ablative techniques for small renal masses. |
| Q90771471 | Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers |
| Q37025955 | Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma |
| Q38114947 | Current status of minimally invasive radical cystectomy: an outcome-based comparison |
| Q37025948 | Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer |
| Q37765588 | Current status of radiation therapy for bladder cancer |
| Q38169230 | Current status of robotic liver resection: a systematic review. |
| Q38123206 | Current status of sentinel lymph node mapping in the management of cervical cancer. |
| Q38069184 | Current status of sentinel lymph node mapping in the management of endometrial cancer. |
| Q38048823 | Current strategies in the treatment of non-muscle-invasive bladder cancer |
| Q36668237 | Current surgical management of melanoma |
| Q101570288 | Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review |
| Q37945642 | Current surgical treatment of non-small-cell lung cancer. |
| Q37483961 | Current systemic therapy for metastatic melanoma |
| Q34734296 | Current therapy and future prospects in lymphoma |
| Q28248896 | Current treatment for Ewing's sarcoma |
| Q37960909 | Current treatment of metastatic bladder cancer and future directions |
| Q34670080 | Current treatment options for dermatofibrosarcoma protuberans |
| Q35843726 | Current treatment options for endometrial cancer |
| Q37202781 | Current treatment strategies for endometrial cancer |
| Q35782925 | Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection |
| Q83951250 | Current trends in the management of malignant pleural mesothelioma |
| Q38154956 | Current uses of radiation therapy in patients with primary CNS lymphoma |
| Q38123202 | Current, new and novel therapy for castration-resistant prostate cancer. |
| Q37118944 | Cutaneous head and neck melanoma: the old and the new. |
| Q34459043 | Cutaneous malignant melanoma: facts about sunbeds and sunscreen |
| Q37004652 | CyberKnife robotic radiosurgery system for tumor treatment |
| Q74450315 | Cyberknife image-guided radiosurgery system successful |
| Q44908063 | Cyclin A1, a promising tumor antigen: the devil is in the amino acids |
| Q35987775 | Cytokine and vaccine therapy of kidney cancer |
| Q36573863 | Cytoreductive nephrectomy in metastatic renal cell carcinoma |
| Q38176034 | Cytoreductive nephrectomy: past, present and future |
| Q53411449 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal cancer: choosing the right candidates. |
| Q37965643 | Cytotoxic/tumor suppressor role of zinc for the treatment of cancer: an enigma and an opportunity |
| Q37788247 | DMBA-induced hamster buccal pouch carcinoma and VX2-induced rabbit cancer as a model for human oral carcinogenesis |
| Q36235566 | DNA methylation: its role in lung carcinogenesis and therapeutic implications |
| Q84632580 | DNase1: a new personalized therapy for cancer? |
| Q57129450 | Dabrafenib and trametinib for the treatment of non-small cell lung cancer |
| Q38364837 | Dabrafenib in the treatment of metastatic or unresectable melanoma |
| Q36974670 | Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals |
| Q35918431 | Darbepoetin alfa for the treatment of cancer-related anemia: an update |
| Q38056750 | Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy |
| Q35089120 | Darbepoetin alfa: potential role in managing anemia in cancer patients |
| Q90585109 | Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy |
| Q37952238 | Debulking surgery in advanced melanoma |
| Q104561160 | Deciding on the duration of adjuvant therapy in gastrointestinal stromal tumor |
| Q90998574 | Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options |
| Q38048818 | Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review |
| Q34257184 | Decitabine for acute myeloid leukemia |
| Q78721305 | Decitabine has promising clinical activity in chronic myeloid leukemia |
| Q34088403 | Decitabine in the treatment of myelodysplastic syndromes. |
| Q54469914 | Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. |
| Q51024921 | Defining the role of the immune system in cancer treatment: highlights from the Immunochemotherapy Conference. |
| Q93197909 | Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion |
| Q37508032 | Definition and management of patients with bladder cancer who fail BCG therapy |
| Q37642777 | Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer |
| Q74450672 | Delcath Systems' phase III trial for inoperable cancer is planned at Sydney Melanoma Unit |
| Q35843658 | Demethylation of DNA by decitabine in cancer chemotherapy |
| Q48777590 | Dendritic cell immunotherapy for glioblastoma |
| Q38069183 | Dendritic cell immunotherapy in ovarian cancer |
| Q73027776 | Dendritic cell therapy of cancer: can it fulfill its promise? |
| Q37628701 | Dendritic cell vaccination as a treatment modality for melanoma |
| Q36752018 | Dendritic cell vaccines for leukemia patients |
| Q36185636 | Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway |
| Q28280510 | Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders |
| Q36066136 | Denileukin diftitox: a concise clinical review |
| Q37970800 | Denosumab for the management of bone disease in patients with solid tumors |
| Q53094814 | Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis. |
| Q47681398 | Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas |
| Q38090734 | Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. |
| Q38783355 | Dermoscopy in the era of dermato-oncology: from bed to bench side and retour |
| Q37449070 | Desmoid tumors: need for an individualized approach |
| Q91239746 | Desmoplastic melanoma: a brief review and the efficacy of immunotherapy |
| Q31132701 | Detecting tumor progression in glioma: Current standards and new techniques. |
| Q37866765 | Detection of lymph node metastases in esophageal cancer. |
| Q84962655 | Determination of cut-offs for circulating tumor cell measurement in metastatic cancer |
| Q33382467 | Determining glioma response to radiation therapy using recombinant peptides |
| Q39005975 | Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. |
| Q89419360 | Determining treatment intensity in elderly patients with multiple myeloma |
| Q38851464 | Developing immunotherapeutic strategies to target brain tumors |
| Q36352085 | Developing innovative strategies for advanced transitional cell carcinoma of the bladder |
| Q37038884 | Development of antiangiogenic agents for ovarian cancer. |
| Q98612578 | Development of chemotherapeutics for unresectable advanced esophageal cancer |
| Q36788512 | Development of histone deacetylase inhibitors for cancer treatment |
| Q37854706 | Development of targeted therapy for squamous cell carcinomas of the head and neck |
| Q34634149 | Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer |
| Q35843703 | Developments in combination chemotherapy for colorectal cancer |
| Q37812604 | Developments in intravesical therapy for non-muscle-invasive bladder cancer |
| Q92470926 | Developments in predictive biomarkers for hepatocellular carcinoma therapy |
| Q38088005 | Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer |
| Q91165246 | Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma |
| Q34715947 | Dexrazoxane for anthracycline extravasation |
| Q79147379 | Diabetes insipidus |
| Q37774360 | Diagnosis and individualized therapy of neoplastic meningitis |
| Q36752033 | Diagnosis and therapy of oral squamous cell carcinoma. |
| Q33196127 | Diagnosis and treatment of carcinoid tumors |
| Q124844415 | Diagnostic accuracy of arterial spin labeling in differentiating between primary central nervous system lymphoma and high-grade glioma: a systematic review and meta-analysis |
| Q38090739 | Diarrhea associated with afatinib: an oral ErbB family blocker |
| Q41392733 | Die-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance |
| Q37038892 | Diet and prostate cancer risk reduction |
| Q49844676 | Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. |
| Q94460148 | Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype |
| Q38712623 | Differential diagnosis between primary lung squamous cell carcinoma and pulmonary metastasis of head and neck squamous cell carcinoma |
| Q37988566 | Differentiated thyroid cancers: a comprehensive review of novel targeted therapies |
| Q57108651 | Digital breast tomosynthesis (3D mammography) for breast cancer screening and for assessment of screen-recalled findings: review of the evidence |
| Q48518423 | Digital mammography in breast cancer screening: a step forward? |
| Q93149583 | Direct KRAS inhibition: progress, challenges and a glimpse into the future |
| Q84451553 | Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues |
| Q37866789 | Dissection of lymph node metastases in esophageal cancer. |
| Q99353679 | Distinguishing multiple lung primaries from intra-pulmonary metastases and treatment implications |
| Q37687392 | Do stem-like cells play a role in drug resistance of sarcomas? |
| Q38152466 | Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer? |
| Q38081246 | Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma? |
| Q35160177 | Docetaxel (taxotere) in the treatment of prostate cancer |
| Q74450341 | Docetaxel improves survival and reduces risk of relapse in node-positive early-stage breast cancer |
| Q36066126 | Docetaxel in advanced non-small cell lung cancer. |
| Q36118370 | Docetaxel in the management of ovarian cancer |
| Q37202758 | Docetaxel in the management of patients with head and neck squamous cell carcinoma |
| Q37242661 | Docetaxel in the treatment of advanced non-small-cell lung cancer. |
| Q36235546 | Docetaxel in the treatment of breast cancer: current experience and future prospects. |
| Q37799821 | Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? |
| Q53117857 | Does fluorodeoxyglucose PET add to the management of the neck following curative radiotherapy in head and neck cancer compared with computed tomography? |
| Q42425640 | Does obesity promote the development of colorectal cancer? |
| Q50067099 | Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer? |
| Q52725508 | Dose intense chemotherapy in the management of poor prognosis and relapsed testicular cancer: experiences and controversies. |
| Q35843716 | Dose-escalated 3D conformal radiotherapy in prostate cancer |
| Q34734533 | Dose-intensive chemotherapy in advanced adult soft tissue sarcoma |
| Q38662393 | Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia |
| Q37845838 | Dosimetric and clinical review of helical tomotherapy |
| Q38700109 | Down-regulation of liver-intestine cadherin enhances noscapine-induced apoptosis in human colon cancer cells |
| Q36636645 | Drug target interaction of tubulin-binding drugs in cancer therapy |
| Q38575008 | Drug transporters in breast cancer: response to anthracyclines and taxanes. |
| Q36407473 | Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions |
| Q74450494 | Drug used during radiotherapy helps reduce dry mouth problem |
| Q37300028 | Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead |
| Q34500113 | Drugs acting on homeostasis: challenging cancer cell adaptation |
| Q38132242 | Ductal carcinoma in situ: an overview |
| Q38457619 | Ductal carcinoma in situ: treatment or active surveillance? |
| Q91547132 | Durvalumab for the treatment of non-small cell lung cancer |
| Q52682808 | Durvalumab in urothelial cancers. |
| Q79870160 | Dynamic sentinel lymph node biopsy in penile cancer |
| Q74450669 | Dynavax and Coley Pharmaceutical Group initiate rituximab combination trials |
| Q38030598 | Dyslipidemia, statins and prostate cancer |
| Q37799824 | EGF receptor in lung cancer: a successful story of targeted therapy |
| Q38068204 | EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer |
| Q92015422 | EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy |
| Q34734109 | EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer |
| Q74450337 | ERBITUX as a single agent and in combination in colorectal carcinoma |
| Q37038888 | ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer |
| Q36532102 | Early clinical detection of ovarian cancer: a review of the evidence |
| Q92971518 | Early detection and imaging strategies to reveal and target developing pancreatic cancer |
| Q87066092 | Early detection of prostate cancer: can we have our cake and eat it too? |
| Q37357314 | Early development of sunitinib in hepatocellular carcinoma |
| Q36817144 | Early gene expression of acute myeloid leukemia in response to chemotherapy |
| Q34022130 | Early outcomes data for accelerated partial breast irradiation using balloon brachytherapy |
| Q37782092 | Early recurrence risk: aromatase inhibitors versus tamoxifen. |
| Q37705426 | Early-stage cervical cancer: is surgery better than radiotherapy? |
| Q38545561 | Echo-endoscopic lymph node staging in lung cancer: an endoscopic alternative |
| Q38162286 | Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. |
| Q36842760 | Effect of cancer and cancer treatment on human reproduction |
| Q33246022 | Effect of laser-induced thermotherapy on liver metastases |
| Q35132743 | Effect of lymph node dissection on the outcomes of upper tract urothelial carcinomas: a meta-analysis |
| Q36499247 | Effects of 5-fluorouracil adjuvant treatment of colon cancer |
| Q36668265 | Effects of adjuvant aromatase inhibitor therapy on lipid profiles |
| Q86109484 | Effects of aspirin on cancer initiation and progression |
| Q37799823 | Effects of continued tobacco use during treatment of lung cancer |
| Q96307567 | Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives |
| Q38068587 | Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach |
| Q37338228 | Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer |
| Q42964655 | Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer |
| Q37894687 | Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer |
| Q38386866 | Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma |
| Q37965634 | Efficacy of instillations with chemotherapy or immunotherapy following endoscopic resection for upper tract urothelial carcinoma |
| Q81458260 | Elderly lung cancer patients: what treatment strategies? |
| Q34020065 | Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma |
| Q31036622 | Electron intraoperative treatment in patients with early-stage breast cancer: data update |
| Q38139998 | Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma |
| Q91074936 | Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma |
| Q38055498 | Emerging agents for the treatment of mantle cell lymphoma |
| Q37945645 | Emerging antiangiogenic therapies for non-small-cell lung cancer |
| Q37909368 | Emerging application of stereotactic body radiation therapy for gynecologic malignancies |
| Q37934972 | Emerging applications of stereotactic body radiation therapy for head and neck cancer |
| Q37656229 | Emerging biological observations in prostate cancer |
| Q46537162 | Emerging data on improving response to hormone therapy: the role of novel targeted agents |
| Q38344404 | Emerging drugs for diffuse large B-cell lymphoma |
| Q38068583 | Emerging personalized approaches for the management of advanced urothelial carcinoma |
| Q37134438 | Emerging role of intensity-modulated radiation therapy in anorectal cancer |
| Q31139823 | Emerging role of new transgenic mouse models in glioma research |
| Q35015611 | Emerging role of pemetrexed in ovarian cancer |
| Q38096479 | Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer |
| Q53703490 | Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers. |
| Q38653045 | Emerging targeted therapies in non-small cell lung cancer |
| Q38587958 | Emerging therapeutic approaches in renal cell carcinoma |
| Q38551391 | Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma |
| Q34660607 | Emerging therapeutic targets for synovial sarcoma |
| Q37598947 | Emerging therapies for B-cell non-Hodgkin lymphoma |
| Q34659806 | Emerging therapies for adult soft tissue sarcoma. |
| Q37030800 | Emerging therapies for malignant glioma |
| Q37134426 | Emerging therapies for melanoma |
| Q38930155 | Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective. |
| Q92423811 | Emotions in the room: common emotional reactions to discussions of poor prognosis and tools to address them |
| Q33204409 | Empowering people with cancer |
| Q73334870 | Encouraging results for Plenaxis in prostate cancer trial |
| Q74450419 | Encouraging results from phase I trial of GVAX |
| Q37952239 | End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. |
| Q35987790 | Endocrine therapy and other targeted therapies for metastatic breast cancer |
| Q35918469 | Endocrine therapy for early breast cancer |
| Q37385376 | Endocrine therapy for the treatment of postmenopausal women with breast cancer |
| Q39038223 | Endocrine therapy in epithelial ovarian cancer |
| Q38658655 | Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence |
| Q39290229 | Endoscopic management of upper-tract urothelial carcinoma |
| Q98564016 | Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature |
| Q38186132 | Endoscopic treatment options for cholangiocarcinomas |
| Q38081236 | Endotrophin in the tumor stroma: a new therapeutic target for breast cancer? |
| Q38101608 | Enhancing radiation therapy for patients with glioblastoma |
| Q90726577 | Entrectinib for the treatment of metastatic NSCLC: safety and efficacy |
| Q34969264 | Environment, phenotype and genetics: risk factors associated with BCC of the skin |
| Q35576187 | Epidemiology and clinical burden of acute myeloid leukemia |
| Q30235358 | Epidemiology and treatment patterns of epithelial ovarian cancer |
| Q53222749 | Epidemiology of brain tumors. |
| Q79449946 | Epidermal growth factor receptor as a target for cancer therapy |
| Q92632013 | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer |
| Q38594474 | Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer |
| Q38002466 | Epidermal growth factor vaccine in non-small-cell lung cancer |
| Q36974707 | Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents |
| Q35728653 | Epirubicin as adjuvant therapy in breast cancer. |
| Q36334861 | Epoetin alfa: basic biology and clinical utility in cancer patients |
| Q37183442 | Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia |
| Q37242676 | Epothilones in breast cancer: current status and future directions |
| Q36636619 | Epratuzumab in the therapy of oncological and immunological diseases |
| Q38720593 | Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options |
| Q90210057 | Erdafitinib for the treatment of urothelial cancer |
| Q37752390 | Erectile dysfunction after robot-assisted radical prostatectomy |
| Q38722807 | Eribulin in advanced liposarcoma and leiomyosarcoma |
| Q38213846 | Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review |
| Q35160181 | Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase |
| Q38101604 | Erlotinib in the first-line treatment of non-small-cell lung cancer |
| Q36284485 | Erlotinib in the treatment of non-small cell lung cancer |
| Q37256825 | Esophageal cancer: current and emerging therapy modalities. |
| Q37873466 | Estrogens, estrogen receptors and melanoma |
| Q83159696 | European Cancer Organisation backs proposals to revise EU Clinical Trials Directive |
| Q38618772 | Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis |
| Q37242679 | Evaluating the link between stem cells and breast cancer |
| Q39243591 | Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer |
| Q37159499 | Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18. |
| Q37508003 | Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma |
| Q37931887 | Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis |
| Q91948812 | Evolution in the management of soft tissue sarcoma: classification, surgery and use of radiotherapy |
| Q37300030 | Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma |
| Q37952240 | Evolution of care for patients with relapsed glioblastoma. |
| Q33557413 | Evolution of systemic therapy for advanced pancreatic cancer |
| Q34734172 | Evolving classification of renal cell neoplasia |
| Q35843686 | Evolving role of chemoradiation in the adjuvant treatment of gastric cancer |
| Q35611876 | Evolving role of pegylated interferons in metastatic renal cell carcinoma |
| Q34185007 | Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies |
| Q104517252 | Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy |
| Q53249055 | Evolving treatment landscape in metastatic renal cell carcinoma: where are we now? |
| Q36668260 | Evolving treatment paradigms for locally advanced and metastatic prostate cancer |
| Q38823374 | Evolving treatments for advanced gastric cancer: appraisal of the survival trend |
| Q36605391 | Evolving use of radiotherapy and radiosurgery in the treatment of pituitary adenomas |
| Q37134450 | Ewing sarcoma: prognostic criteria, outcomes and future treatment |
| Q84386241 | Ewing's sarcoma origin: from duel to duality |
| Q34734021 | Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment |
| Q36334866 | Exisulind in the treatment of prostate cancer |
| Q53500035 | Expanding role of bisphosphonates in the management of early breast cancer. |
| Q75195177 | Expanding role of chemokines and their receptors in cancer |
| Q83295736 | Expanding role of nanotechnology in the management of colorectal cancer |
| Q38995032 | Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge |
| Q37765584 | Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients |
| Q38156190 | Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer |
| Q92638032 | Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy |
| Q50782958 | Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. |
| Q37202764 | Exploration of treatment options for the management of stage I testicular seminoma |
| Q38069181 | Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients |
| Q85262602 | Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma |
| Q91743773 | Exploring the link between diabetes and pancreatic cancer |
| Q38246950 | Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer |
| Q34537170 | Expression profiling for bladder cancer: strategies to uncover prognostic factors. |
| Q36500530 | Extended adjuvant therapy with letrozole: reducing the risk of recurrence |
| Q28067135 | External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma |
| Q38439669 | Extra-CNS metastasis from glioblastoma: a rare clinical entity |
| Q34734306 | Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century |
| Q83074000 | Extreme hypofractionation for prostate cancer |
| Q74450483 | FDA approves Novartis' Gleevec |
| Q74450664 | FDA approves ZOMETA for treatment of cancer-related bone complications |
| Q78721289 | FDA approves extra safe chemotherapy drug |
| Q78721283 | FDA grants orphan-drug status to Aeterna's Neovastat for kidney cancer |
| Q74450434 | FDA grants priority review for ZOMETA |
| Q38247470 | FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer |
| Q36235597 | Factors increasing local recurrence in breast-conserving surgery. |
| Q38190107 | Factors influencing decisions about surgical treatment of cervical precancerous lesions |
| Q39012295 | Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists |
| Q38995035 | Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin |
| Q45230424 | Family history and the risk of cancer: genetic factors influencing multiple cancer sites |
| Q39430455 | Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. |
| Q36879155 | Fertility preservation and minimizing reproductive damage in cancer survivors |
| Q38843979 | Fertility preservation in women with CNS tumors |
| Q36352064 | Fertility-sparing therapy for young women with endometrial cancer |
| Q38081247 | Fibroblastic tumors of intermediate malignancy in childhood |
| Q44171693 | Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk group |
| Q36500556 | First- and second-line therapy of metastatic colorectal cancer |
| Q47868774 | First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma |
| Q54186267 | First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF? |
| Q37449024 | First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype |
| Q37656214 | First-line treatment of advanced ovarian cancer: current research and perspectives. |
| Q35668071 | Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols. |
| Q44369304 | Fluoropyrimidine resistance in colon cancer. |
| Q38264786 | Focal cryotherapy of localized prostate cancer: a systematic review of the literature |
| Q37965637 | Focal therapy for prostate cancer: patient selection and evaluation |
| Q99410429 | Focused nutrition clinic for severely malnourished children with cancer is feasible and effective in high-volume, resource-constrained settings |
| Q35728677 | Follow-up care in breast cancer |
| Q38055500 | Follow-up procedures for non-muscle-invasive bladder cancer: an update |
| Q38062023 | Follow-up recommendations and risk-reduction initiatives for Lynch syndrome |
| Q91718677 | Foreword |
| Q95597485 | Foreword |
| Q37982438 | Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting |
| Q37316977 | Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting |
| Q37577925 | Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer |
| Q36352100 | From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy |
| Q39041541 | From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage? |
| Q38191990 | From radiobiology to technology: what is changing in radiotherapy for prostate cancer |
| Q47446760 | From tumor size and HER2 status to systems oncology for very early breast cancer treatment |
| Q34734508 | Fulvestrant (Faslodex): current status in the therapy of breast cancer. |
| Q54979338 | Fulvestrant for the treatment of advanced breast cancer. |
| Q36185614 | Fulvestrant in the treatment of postmenopausal women with advanced breast cancer |
| Q36752044 | Function and organ preservation in adult cancers of the head and neck |
| Q39021988 | Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. |
| Q90272660 | Further insights into testicular germ cell tumor oncogenesis: potential therapeutic targets |
| Q92010963 | Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development |
| Q37705412 | Fusion imaging for parathyroid localization in primary hyperparathyroidism |
| Q57163702 | Future applications of FGF/FGFR inhibitors in cancer |
| Q36407462 | Future chemotherapy and radiotherapy options in head and neck cancer |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q74450363 | GPC Biotech receives Orphan Medicinal Product Designation |
| Q78721279 | GSIs described as most important finding in cancer-targeting research |
| Q74450442 | GTx begins next phase of clinical trials for prostate cancer |
| Q38009854 | Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management. |
| Q35641188 | Gefitinib (Iressa): a novel treatment for non-small cell lung cancer |
| Q37357287 | Gefitinib for the treatment of non-small-cell lung cancer |
| Q37449013 | Gefitinib in the treatment of advanced non-small-cell lung cancer |
| Q35782899 | Gemcitabine (Gemzar) in non-small cell lung cancer |
| Q36381261 | Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer? |
| Q36185611 | Gemcitabine in metastatic breast cancer |
| Q37134412 | Gemcitabine in the treatment of metastatic pancreatic cancer |
| Q35070414 | Gemcitabine in transitional cell carcinoma of the urothelium |
| Q36407477 | Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma. |
| Q35034815 | Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia |
| Q99208736 | Gender discrepancies in bladder cancer: potential explanations |
| Q39022105 | Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma |
| Q37004685 | Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors |
| Q36532106 | Gene therapeutics: the future of brain tumor therapy? |
| Q74450374 | Gene therapy for prostate cancer |
| Q34734147 | Gene therapy for superficial bladder cancer |
| Q36532089 | Gene therapy in gynecological cancer |
| Q34734186 | Genetic alterations and chemotherapeutic response in human diffuse gliomas |
| Q42909155 | Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics |
| Q38123207 | Genetic changes in nonepithelial ovarian cancer |
| Q37202787 | Genetic polymorphisms and endometrial cancer risk |
| Q38622172 | Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer |
| Q47884776 | Genetic testing in women with breast cancer: implications for treatment |
| Q44319257 | Genetically engineered Newcastle disease virus for prostate cancer: a magic bullet or a misfit |
| Q36689118 | Genistein and resveratrol: mammary cancer chemoprevention and mechanisms of action in the rat. |
| Q22241482 | Genome-wide association studies: how predictable is a person’s cancer risk? |
| Q37085992 | Genotype-guided adjuvant endocrine therapy: new tricks from an old drug? |
| Q74450394 | Genta initiates trials with Genasense |
| Q74450431 | Genzyme Molecular Oncology receives patent for melanoma immunogens |
| Q38554534 | Geographic/ethnic variability of chromosomal and molecular abnormalities in leukemia |
| Q80273852 | Getting innovation to patients |
| Q87047731 | Getting to the root of the problem: the causes of relapse in multiple myeloma |
| Q37030797 | Glioblastoma multiforme: evidence-based approach to therapy |
| Q37752381 | Glioma stem cell signaling: therapeutic opportunities and challenges |
| Q38068209 | Global and health-related quality of life after intensity-modulated radiation therapy for head and neck cancer |
| Q37873462 | Global experience with ixabepilone in breast cancer |
| Q74450407 | GlycoDesign expands phase II clinical trials for GD0039 |
| Q30703386 | Gold(III) complexes as a new family of cytotoxic and antitumor agents. |
| Q47569503 | Group support in breast cancer: realistic hope, realistic benefits |
| Q38153447 | HER2 and lung cancer |
| Q34974436 | HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies |
| Q34734329 | Hairy cell leukemia: treatment prospects |
| Q59377160 | Harmonizing adult and pediatric approaches to the treatment of soft-tissue sarcoma |
| Q90594754 | Have treatment protocols for primary CNS lymphoma advanced in the past 10 years |
| Q36532126 | Head and neck cancer: past, present and future. |
| Q79186885 | Head and neck oncology: what the past decade has taught us |
| Q36185629 | Head and neck squamous cell carcinoma: optimizing the therapeutic index. |
| Q38223247 | Health technology assessment in evolution - focal therapy in localised prostate cancer |
| Q91731494 | Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review |
| Q35204956 | Health-related quality of life in colorectal cancer patients |
| Q48037262 | Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology |
| Q37331708 | Heat-shock protein vaccines as active immunotherapy against human gliomas |
| Q92680778 | Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia |
| Q35641221 | Helicobacter pylori and molecular mechanisms of gastric carcinogenesis: targets for prevention and therapy |
| Q38209850 | Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma |
| Q82262232 | Helicobacter pylori eradication for gastric cancer prevention |
| Q30235359 | Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. |
| Q38140001 | Hematological malignancies: role of miRNAs and their in silico aspects |
| Q74450684 | Hemosol receives clearance to begin study of HEMOLINK |
| Q36668229 | Hepatocellular cancer in HIV-infected individuals: tomorrow's problem? |
| Q38246965 | Hepatocellular carcinoma: systemic therapies and future perspectives |
| Q37577908 | Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer. |
| Q104744118 | High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL) |
| Q36499211 | High- and low-penetrance cutaneous melanoma susceptibility genes. |
| Q37845833 | High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors |
| Q35660641 | High-dose chemotherapy and stem cell transplantation for advanced testicular cancer |
| Q36407446 | High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma |
| Q38559388 | High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis |
| Q36842765 | High-intensity focused ultrasound ablation of breast cancer |
| Q36334903 | High-intensity focused ultrasound as a treatment option in renal cell carcinoma |
| Q50249699 | High-intensity focused ultrasound: a potential salvage treatment for recurrent prostate cancer following radiotherapy |
| Q37656210 | High-intensity focused ultrasound: where are we and where to from here? |
| Q89420712 | Highlighting the need for reliable clinical trials in glioblastoma |
| Q46194868 | Highlights from the 3rd Breast-Gynecological International Cancer Conference 2011. |
| Q87664811 | Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancer |
| Q53171093 | Highlights of the 2nd European Lung Cancer Conference. |
| Q50767949 | Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA. |
| Q51141224 | Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer. |
| Q37118947 | Histone deacetylase inhibitors in lymphoma and solid malignancies |
| Q41823823 | Hitting the bull's eye: targeting HMGA1 in cancer stem cells |
| Q53068019 | Hormonal therapy and radiation for prostate cancer: is it safe? |
| Q34138275 | Hormonal therapy for prostate cancer: past, present and future |
| Q36352073 | Hormonal therapy in epithelial ovarian cancer. |
| Q38030590 | Hormonal therapy in gynecological sarcomas |
| Q34734067 | Hormonal treatment of endometrial carcinoma |
| Q38169220 | Hot flushes in women with breast cancer: state of the art and future perspectives |
| Q88850871 | How can plasma RNA be used to diagnose prostate cancer? |
| Q37782098 | How can survival be improved in localized osteosarcoma? |
| Q39065451 | How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma |
| Q44452857 | How could a drug used to treat alcoholism also be effective against glioblastoma? |
| Q87966149 | How important is 'reason' in influencing adjuvant chemotherapy decisions by patients? |
| Q38830389 | How might treatment of ALK-positive non-small cell lung cancer change in the near future? |
| Q83521503 | How to carry out retrospective studies in metastatic renal cell cancer: two caveats that should be avoided |
| Q94546106 | How to face cancer treatment in the COVID-19 era |
| Q37854717 | How to improve the implementation of guidelines on cancer-related thrombosis |
| Q89720582 | How to use neoadjuvant medical treatment to maximize surgery in melanoma |
| Q54409890 | How will the CHHiP trial affect the future of prostate radiotherapy? |
| Q37614579 | HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment |
| Q74450366 | Human Genome Sciences announces clearance of IND application for LymphoRad |
| Q37909359 | Human papillomavirus testing and genotyping in cervical screening |
| Q36817148 | Human papillomavirus therapeutic vaccines in head and neck tumors |
| Q78380619 | Hybridon and Aegera collaborate to develop antisense drug |
| Q34171747 | Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. |
| Q37965630 | Hydroxyurea: a key player in cancer chemotherapy |
| Q91489421 | Hype or hope? The strange case of platinum salts' renaissance in breast cancer |
| Q37385380 | Hyperthermia as an adjunctive treatment for soft-tissue sarcoma. |
| Q38682106 | Hyperthermia for non-muscle invasive bladder cancer. |
| Q34356395 | Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data |
| Q57108643 | Hypofractionated radiation treatment in the management of breast cancer |
| Q38030596 | Hypofractionated radiotherapy in prostate cancer |
| Q38264783 | Hypofractioned radiotherapy in prostate cancer: is it the next step? |
| Q41848171 | Hypoxic regulation of metabolism offers new opportunities for anticancer therapy |
| Q44134557 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole |
| Q49185595 | IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications |
| Q74450404 | IDM confirms significant results in bladder cancer program |
| Q34734040 | IMRT in the treatment of head and neck cancer: is the present already the future? |
| Q35987738 | Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease |
| Q33371489 | Ibritumomab tiuxetan for non-Hodgkin's lymphoma |
| Q35059440 | Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis? |
| Q38187487 | Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells. |
| Q36263947 | Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping |
| Q47558551 | Identifying clinical risk in low grade gliomas and appropriate treatment strategies, with special emphasis on the role of surgery |
| Q96582066 | Identifying effective drug combinations for patients with acute myeloid leukemia |
| Q92429568 | Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma |
| Q37024527 | Identifying the risk factors for late-stage head and neck cancer |
| Q82262259 | Image-guided brachytherapy for cervix cancer: from Manchester to Melbourne |
| Q80273836 | Imaging |
| Q38088001 | Imaging and resectability issues of sinonasal tumors. |
| Q36284526 | Imaging breast cancer response during neoadjuvant systemic therapy. |
| Q37866792 | Imaging changes after stereotactic body radiation therapy for lung and liver tumors |
| Q38266811 | Imaging evaluation of lymphadenopathy and patterns of lymph node spread in head and neck cancer. |
| Q36500544 | Imaging findings of renal cell carcinoma |
| Q37546036 | Imaging modalities for prostate cancer |
| Q89420663 | Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies |
| Q31062683 | Imaging of the pituitary and sella turcica |
| Q37183434 | Imatinib mesylate for the treatment of chronic myeloid leukemia |
| Q37752353 | Imatinib mesylate for the treatment of gastrointestinal stromal tumor |
| Q38725366 | Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. |
| Q79878118 | Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia |
| Q37134430 | Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies |
| Q89283359 | Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges |
| Q92691233 | Immune checkpoint inhibitors: a new era for esophageal cancer |
| Q92470683 | Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled |
| Q38212149 | Immune therapies for malignant mesothelioma |
| Q38249339 | Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness |
| Q59357214 | Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review |
| Q98161696 | Immune-related adverse events: what we've learned and where we're heading |
| Q30235360 | Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review |
| Q38451287 | Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. |
| Q38947116 | Immunological effects of chemotherapy and radiotherapy against brain tumors |
| Q36500548 | Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma |
| Q79444229 | Immunoprevention of cancer: time to reconsider timing of vaccination against cancer |
| Q38069182 | Immunosuppression and risk of cervical cancer |
| Q39120161 | Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go? |
| Q28301672 | Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now? |
| Q51823843 | Immunotherapy advances for mesothelioma treatment. |
| Q37159509 | Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma |
| Q38633525 | Immunotherapy and targeted therapy for cervical cancer: an update |
| Q73027798 | Immunotherapy for colorectal cancer |
| Q36284489 | Immunotherapy for human glioma: innovative approaches and recent results |
| Q39351008 | Immunotherapy for malignant mesothelioma: Reality check |
| Q37183451 | Immunotherapy for renal cell cancer in the era of targeted therapy |
| Q38425054 | Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond |
| Q34734316 | Immunotherapy of chronic lymphocytic leukemia |
| Q36689152 | Immunotherapy of multiple myeloma: the start of a long and tortuous journey |
| Q37086013 | Immunotherapy opportunities in ovarian cancer. |
| Q36636651 | Immunotherapy options in metastatic renal cell cancer: where we are and where we are going. |
| Q38242271 | Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? |
| Q35160235 | Immunotherapy: new options in breast cancer treatment |
| Q35918473 | Impact and treatment of cancer during pregnancy |
| Q37642792 | Impact of anti-angiogenic treatments on metastatic renal cell carcinoma |
| Q84386238 | Impact of nanotechnology in breast cancer |
| Q35204983 | Impact of proapoptotic proteins Bax and Bak in tumor progression and response to treatment |
| Q38749004 | Impact of sarcopenia in the management of urological cancer patients. |
| Q40167778 | Impact of tumor size on the outcome of patients with small renal cell carcinoma |
| Q47331469 | Impact on society |
| Q104109689 | Implementing continued radiation therapy for cancer management in low resource countries during and after the COVID-19 crisis |
| Q38765017 | Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer |
| Q37931898 | Implication of miRNA in the diagnosis and treatment of breast cancer. |
| Q74450348 | Improved survival with combined chemotherapy and radiation in advanced lung cancer patients |
| Q44424119 | Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies |
| Q38114945 | Improving bladder cancer patient care: a pharmacoeconomic perspective |
| Q37988564 | Improving end-of-life care for head and neck cancer patients |
| Q38344456 | Improving outcomes for neurofibromatosis 1-associated brain tumors |
| Q37118967 | Improving outcomes in patients with advanced renal cell carcinoma |
| Q38823508 | Improving patient outcomes to targeted therapies in melanoma |
| Q47978964 | Improving postoperative radiotherapy following radical prostatectomy |
| Q37894684 | Improving selection of appropriate urinary diversion following radical cystectomy for bladder cancer. |
| Q38162922 | Improving surgical outcomes in renal cell carcinoma involving the inferior vena cava |
| Q54454234 | Improving the accuracy in prognosis for Burkitt lymphoma patients. |
| Q97675838 | Improving the accuracy of prognostication in chronic myelomonocytic leukemia |
| Q62494975 | Improving the early diagnosis of early nodular melanoma: can we do better? |
| Q38010798 | Improving triage and management of patients with skin cancer: challenges and considerations for the future. |
| Q44897058 | Improving urologic cancer care through telemedicine |
| Q37765585 | In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma |
| Q38226689 | In squamous cell head and neck cancer: which platinum, how much and how often? |
| Q59011730 | Inadequacy of tissue microarrays for the immunohistochemical detection of cancer stem cells in solid tumors: a viewpoint |
| Q40213826 | Incorporating a compact proton therapy unit into an existing National Cancer Institute-designated comprehensive cancer center |
| Q48345093 | Incorporating age into International Germ Cell Consensus Classification (IGCCC): a time to move forward? |
| Q92772045 | Incorporating molecular biomarkers into clinical practice for gastric cancer |
| Q64136443 | Increased cancer incidence in Holocaust survivors and the implications for survivors of other extreme events |
| Q54269318 | Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact? |
| Q38783950 | Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma. |
| Q48529991 | Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma |
| Q28268862 | Indium-111 capromab pendetide in the management of recurrent prostate cancer |
| Q34734072 | Individualized cancer therapy: molecular approaches to the prediction of tumor response |
| Q92144515 | Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology |
| Q44034598 | Individualizing therapy for oropharyngeal cancer patients |
| Q35204947 | Individualizing therapy in gastric cancer |
| Q36613979 | Induction chemotherapy in the management of squamous cell carcinoma of the head and neck |
| Q36974700 | Inflammation and lung carcinogenesis: applying findings in prevention and treatment. |
| Q37134446 | Inflammation in the development of lung cancer: epidemiological evidence |
| Q37577918 | Influence of obesity on breast cancer receptor status and prognosis |
| Q37004664 | Inhibition of angiogenesis and invasion in malignant gliomas |
| Q36950485 | Inhibitor of apoptosis proteins as targets for anticancer therapy |
| Q58610208 | Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries |
| Q61937940 | Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries |
| Q38665500 | Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia |
| Q36950482 | Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer |
| Q43825935 | Integrated analysis of miRNA and mRNA profiles enables target acquisition in human cancers |
| Q82417364 | Integrating novel agents into the curative treatment of head and neck cancer |
| Q38243178 | Integrating stereotactic body radiation therapy in stage II/III non-small cell lung cancer: is local control important? |
| Q35160199 | Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer |
| Q35089143 | Integrins and extracellular matrix: a novel mechanism of multidrug resistance |
| Q49138961 | Intensity-modulated radiation therapy for head and neck cancer |
| Q80343843 | Intensity-modulated radiation therapy for head and neck cancer |
| Q30437740 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy |
| Q35089147 | Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment |
| Q36499242 | Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics |
| Q37782095 | Intermeshing breast reconstruction and postmastectomy radiation |
| Q37357307 | Intermittent therapy in the palliative treatment of metastatic colorectal cancer. |
| Q91757634 | Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC |
| Q37809863 | Interventions for cognitive deficits in patients with a brain tumor: an update |
| Q36788490 | Intestinal homeostasis and neoplasia studied using conditional transgenesis. |
| Q39041266 | Intra-arterial therapies for liver cancer: assessing tumor response |
| Q38149993 | Intraarterial therapies for primary liver cancer: state of the art. |
| Q52691795 | Intralesional therapy as a treatment for locoregionally metastatic melanoma. |
| Q37774349 | Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications |
| Q37821900 | Intraoperative lymphatic mapping techniques for endometrial cancer |
| Q37934971 | Intraoperative neuromonitoring during thyroidectomy |
| Q34734279 | Intraperitoneal chemotherapy in the management of malignant disease |
| Q37202777 | Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer? |
| Q37316997 | Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies |
| Q80373269 | Intratumoral delivery of genes: a new weapon against cancer? |
| Q36573853 | Intravesical mitomycin C for superficial transitional cell carcinoma |
| Q78721297 | Introgen obtains key patent obtained for p53-targeted chemotherapy |
| Q53459045 | Invadopodia: a new therapeutic target to block cancer metastasis. |
| Q36118441 | Inverted papilloma involving the temporal bone and its association with squamous cell carcinoma: critical analysis of the literature |
| Q36284514 | Investigational agents for epithelial ovarian cancer |
| Q35641192 | Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma |
| Q38893697 | Ipilimumab in melanoma |
| Q61866226 | Ipilimumab in melanoma |
| Q37809856 | Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma |
| Q37782091 | Ipsilateral breast tumor recurrence after breast-conserving therapy |
| Q73561198 | Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC |
| Q35576154 | Irinotecan (Campto®) in the treatment of pancreatic cancer |
| Q34733924 | Irinotecan in the treatment of small cell lung cancer |
| Q34166138 | Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer |
| Q36788474 | Is 18F FDG PET-CT cost effective in lung cancer? |
| Q113277726 | Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic |
| Q37085996 | Is axillary dissection needed in node-positive breast cancer? |
| Q34969194 | Is intra-arterial chemotherapy useful in high-grade gliomas? |
| Q37256829 | Is minimally invasive esophagectomy indicated for cancer? |
| Q45982818 | Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer? |
| Q38114946 | Is photodynamic diagnosis ready for introduction in urological clinical practice? |
| Q38162294 | Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? |
| Q24642523 | Is there a role for complementary therapy in the management of leukemia? |
| Q50498722 | Is there a role for intravenous iron therapy in patients undergoing colorectal cancer resection? |
| Q37614585 | Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue |
| Q37765582 | Is there a role for presurgical therapy for renal cell carcinoma? |
| Q52892989 | Is there an optimal prostate-specific antigen threshold for prostate biopsy? |
| Q30836030 | Issues in the epidemiology of melanoma |
| Q37159488 | Ixabepilone: a new microtubule-targeting agent for breast cancer |
| Q37808703 | JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia |
| Q44473916 | Joint genitourinary cancer symposium between Egyptian and American centers |
| Q37338235 | Jumping higher: is it still possible? The ALTTO trial challenge |
| Q78380596 | KS Biomedix licenses TransMID brain cancer product to Nycomed in European collaboration |
| Q36731435 | Kaposi sarcoma as a model of oncogenesis and cancer treatment. |
| Q38263031 | Key papers in prostate cancer |
| Q37159547 | Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma |
| Q28287394 | Key roles of the OPG-RANK-RANKL system in bone oncology |
| Q74450312 | Ki-67: potential lung cancer biomarker |
| Q51134329 | Kinase Inhibitor 4 Minisymposium summary. |
| Q39377852 | L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis |
| Q38701631 | L1 cell adhesion molecule as a therapeutic target in cancer. |
| Q82623324 | Laparoendoscopic single-site surgery for renal malignancies |
| Q36532084 | Laparoscopic and robotic radical prostatectomy |
| Q73841235 | Laparoscopic colorectal cancer surgery |
| Q45982815 | Laparoscopic nephrectomy for Wilms' tumor. |
| Q37300016 | Laparoscopic pancreatic resection for cancer |
| Q37183455 | Laparoscopic partial nephrectomy in the treatment of renal cell carcinoma: a minimally invasive means to nephron preservation |
| Q48831694 | Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends |
| Q91312306 | Laparoscopic surgery for gastric cancer: where are we now and where are we going? |
| Q35918456 | Laparoscopic surgery for melanoma metastases to the adrenal gland |
| Q35611883 | Laparoscopic surgery for renal cell carcinoma |
| Q37782086 | Lapatinib and breast cancer: current indications and outlook for the future |
| Q28250382 | Lapatinib in the treatment of breast cancer |
| Q37628693 | Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. |
| Q57796986 | Larotrectinib for the treatment of TRK fusion solid tumors |
| Q47254623 | Lasers in skin cancer prophylaxis |
| Q36950474 | Late oral complications following radiotherapy for head and neck cancers |
| Q37765587 | Latest developments in imaging of bladder cancer |
| Q37845830 | Latest developments in limb-salvage surgery in osteosarcoma |
| Q37799829 | Latest developments in targeted therapy for hepatocellular carcinoma. |
| Q38341864 | Leading causes of castration-resistant prostate cancer |
| Q37183439 | Lenalidomide and its role in the management of multiple myeloma |
| Q36573818 | Lenalidomide in multiple myeloma |
| Q41114130 | Lenalidomide in multiple myeloma |
| Q43247044 | Lenalidomide in multiple myeloma |
| Q91470134 | Lenvatinib as a therapy for unresectable hepatocellular carcinoma |
| Q54979570 | Lenvatinib for the treatment of kidney cancer. |
| Q30243995 | Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. |
| Q36352053 | Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer |
| Q34734008 | Letrozole for the management of breast cancer |
| Q36235541 | Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? |
| Q92181465 | Limited treatment options in refractory multiple myeloma: promising therapeutic developments |
| Q36400284 | Limiting the morbidity of inguinofemoral lymphadenectomy in vulvar cancer patients; a review |
| Q38455525 | Linifanib: current status and future potential in cancer therapy |
| Q34588395 | Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases |
| Q35204970 | Lipoxygenase inhibitors for the treatment of pancreatic cancer |
| Q47372761 | Liquid biopsies in gastrointestinal malignancies: when is the big day? |
| Q90165038 | Liquid biopsies in pancreatic cancer |
| Q38981793 | Liver metastases resection for gastric and esophageal tumors: is there enough evidence to go down this path? |
| Q36448689 | Liver resection in the treatment of hepatocellular carcinoma |
| Q41641046 | Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience |
| Q51842624 | Liver-directed therapy in metastatic colorectal cancer. |
| Q53426940 | Living beyond the sword of Damocles: surviving childhood cancer. |
| Q37931903 | Localization of nonpalpable breast lesions |
| Q35152457 | Locally ablative therapies for primary and metastatic liver cancer. |
| Q38194590 | Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies |
| Q36614002 | Locoregional therapy of breast cancer: maximizing control, minimizing morbidity |
| Q37812603 | Long-term management of patients with metastatic renal cell carcinoma on targeted agents |
| Q43804593 | Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? |
| Q90420665 | Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer |
| Q84666522 | Loss of miR-126 is crucial to pancreatic cancer progression |
| Q37873474 | Low-dose radiation therapy of cancer: role of immune enhancement |
| Q37030794 | Low-grade gliomas: management issues |
| Q37628706 | Low-grade oligodendroglioma: current treatments and future hopes |
| Q38514737 | Low-grade serous carcinoma: molecular features and contemporary treatment strategies |
| Q98208300 | Lung cancer management: monitoring and treating resistance development in third generation EGFR TKIs |
| Q100540668 | Luteinized thecoma (thecomatosis) with sclerosing peritonitis: a systematic review of the literature of the last 25 years |
| Q104129504 | Luteinized thecomatosis and other conditions associated with sclerosing peritonitis: a problem in causation, management, and nomenclature |
| Q36284510 | Lycopene and prostate cancer: emerging evidence |
| Q80444992 | Lymph node density: surrogate marker for quality of resection in bladder cancer? |
| Q37642789 | Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era. |
| Q38153435 | Lymph node-positive bladder cancer: surgical, pathologic, molecular and prognostic aspects |
| Q37934976 | Lymph node-positive prostate cancer: current issues, emerging technology and impact on clinical outcome |
| Q36532123 | Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma |
| Q46125923 | Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma |
| Q50499402 | Lymphatic mapping and sentinel node biopsy for melanoma. |
| Q38183884 | Lymphocele: prevalence and management in gynecological malignancies |
| Q36334899 | Lymphocyte therapy of renal cell carcinoma |
| Q37134435 | Lynch syndrome in colorectal cancer patients |
| Q24630130 | MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century |
| Q37642780 | ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer |
| Q36118389 | MRI in the detection and management of breast cancer |
| Q104112173 | MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review |
| Q28259350 | MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma |
| Q39361672 | MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer |
| Q34524915 | MYC in breast tumor progression |
| Q36381278 | MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma |
| Q47949163 | Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways |
| Q58876665 | Magnetic resonance imaging of nasopharyngeal carcinoma |
| Q89187119 | Maintenance and continuous therapy for multiple myeloma |
| Q36352105 | Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer |
| Q38002474 | Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice? |
| Q38222277 | Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents |
| Q38191975 | Maintenance therapy in newly diagnosed multiple myeloma: current recommendations |
| Q38509236 | Maintenance therapy in non-small cell lung cancer |
| Q37338245 | Maintenance treatment in metastatic breast cancer. |
| Q90724731 | Major vessel invasion by thyroid cancer: a comprehensive review |
| Q45858428 | Making gene therapy for osteosarcoma a reality |
| Q88657729 | Making the most of every option in the treatment of ovarian cancer |
| Q36499234 | Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment |
| Q38253484 | Malignant melanoma in elderly patients: biological, surgical and medical issues. |
| Q38810465 | Malignant mesenchymal tumors of the uterus - time to advocate a genetic classification. |
| Q37866786 | Malignant pleural mesothelioma: when is radiation therapy indicated? |
| Q89419025 | Management Strategies for Recurrent Endometrial Cancer |
| Q35782952 | Management and geriatric assessment of cancer in the elderly |
| Q37870929 | Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck |
| Q38176431 | Management for premalignant lesions of the oral cavity |
| Q38190109 | Management for premalignant lesions of the oral cavity. |
| Q34734528 | Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment |
| Q37004660 | Management of Bcr-Abl-positive leukemias with dasatinib |
| Q34734233 | Management of Merkel cell carcinoma |
| Q39439346 | Management of abdominal malignancies: updates from the International Association of Surgeons, Gastroenterologists and Oncologists |
| Q37687386 | Management of adult soft-tissue sarcoma of the extremities and trunk |
| Q37909371 | Management of adults with Wilms' tumor: recommendations based on international consensus |
| Q37894683 | Management of advanced bladder cancer in patients with impaired renal function |
| Q38068210 | Management of advanced lung cancer in resource-constrained settings: a perspective from India |
| Q38178742 | Management of advanced or recurrent cervical cancer: chemotherapy and beyond |
| Q39022303 | Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma |
| Q38701378 | Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ. |
| Q37812612 | Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies |
| Q37952231 | Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib |
| Q38220484 | Management of clinical stage I nonseminomatous germ cell tumors |
| Q35070418 | Management of clinical stage I nonseminomatous germ-cell testis tumors |
| Q61637122 | Management of conjunctival melanoma |
| Q90582461 | Management of early stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty |
| Q37854710 | Management of hematological malignancies in patients affected by renal failure |
| Q34733981 | Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention |
| Q37873470 | Management of high-risk squamous cell carcinoma of the skin |
| Q90675497 | Management of immune-related adverse events resulting from immune checkpoint blockade |
| Q35728692 | Management of local recurrence of breast cancer |
| Q39140601 | Management of long bone metastases: recommendations from the Italian Orthopaedic Society bone metastasis study group. |
| Q37159527 | Management of metastatic germ cell tumors |
| Q34351372 | Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. |
| Q84225071 | Management of metastatic spinal cord compression |
| Q35987747 | Management of muscle-invasive bladder cancer in the elderly |
| Q37799827 | Management of obstructive and perforated colorectal cancer |
| Q96030996 | Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions |
| Q37004680 | Management of optic-hypothalamic gliomas in children: still a challenging problem |
| Q84971459 | Management of patients with advanced bladder cancer following major response to systemic chemotherapy |
| Q38811107 | Management of patients with colorectal liver metastasis in eleven questions and answers |
| Q39300917 | Management of patients with metastasis to the vertebrae: recommendations from the Italian Orthopaedic Society (SIOT) Bone Metastasis Study Group |
| Q38139993 | Management of premalignant lesions of the larynx |
| Q36407468 | Management of prostate cancer. Part 1: chemoprevention |
| Q36448693 | Management of prostate cancer. Part 2: localized and locally advanced disease |
| Q36499259 | Management of prostate cancer. Part 3: metastatic disease. |
| Q91488712 | Management of relapsed ovarian cancer in routine clinical practice: a case study |
| Q37300012 | Management of reproductive needs in cancer patients: clinical perspectives |
| Q91827119 | Management of residual masses in testicular germ cell tumors |
| Q38055494 | Management of salivary gland tumors. |
| Q60685847 | Management of small cell lung cancer |
| Q35728710 | Management of soft tissue sarcomas of the extremities |
| Q37705406 | Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations. |
| Q34185001 | Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project |
| Q84632577 | Management of the small renal mass: what is the most reasonable option? |
| Q36731440 | Management of tumor lysis syndrome in adults |
| Q37812609 | Management of upper urinary tract urothelial carcinoma |
| Q37774354 | Management options for stage I seminoma |
| Q38262193 | Managing GIST in the imatinib era: optimization of adjuvant therapy |
| Q35034823 | Managing locally advanced bladder cancer |
| Q37598939 | Managing malignancies of the external auditory canal |
| Q37765589 | Managing muscle-invasive bladder cancer in the elderly |
| Q38088002 | Managing newly diagnosed follicular lymphoma: state of the art and future perspectives |
| Q57104913 | Managing side effects in adjuvant endocrine therapy for breast cancer |
| Q81777535 | Margins in breast-conserving therapy: have we lost sight of the big picture? |
| Q38625070 | Massive parallel sequencing in sarcoma pathobiology: state of the art and perspectives |
| Q34577219 | Mathematical modeling of cancer progression and response to chemotherapy |
| Q91722799 | Mathematical models of tumor cell proliferation: A review of the literature |
| Q74450323 | Matrix initiates phase II study in hepatocellular carcinoma |
| Q36066182 | Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach. |
| Q38069186 | Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint |
| Q95853644 | Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene |
| Q37988569 | Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia |
| Q38220073 | Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. |
| Q37008871 | Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future |
| Q74450318 | MedImmune initiates phase I/II clinical study with Vitaxin |
| Q38162923 | Medical approaches to non-melanoma skin cancer |
| Q36879146 | Medical management of advanced prostate cancer: a multidisciplinary team approach |
| Q35987782 | Medical treatment of epithelial ovarian cancer |
| Q36788494 | Medical treatment of pancreatic cancer |
| Q38758419 | Medication adherence to oral anticancer drugs: systematic review |
| Q34635409 | Medullary thyroid carcinoma: surgical treatment advances. |
| Q55470101 | Medulloblastoma: need for targeted treatment. |
| Q37202789 | Medulloblastoma: what is the role of molecular genetics? |
| Q35576163 | Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments? |
| Q90489227 | Melanoma immunotherapy: strategies to overcome pharmacological resistance |
| Q38162924 | Melanoma patient self-detection: a review of efficacy of the skin self-examination and patient-directed educational efforts |
| Q34734226 | Melanoma vaccination: state-of-the-art and experimental approaches |
| Q37159517 | Melanoma-induced brain metastases |
| Q36879132 | Melphalan and its role in the management of patients with multiple myeloma. |
| Q37952243 | Meningioma: review of the literature with emphasis on the approach to radiotherapy |
| Q37316995 | Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms |
| Q38541877 | Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. |
| Q37642801 | Metastatic colorectal cancer: recent advances in its clinical management |
| Q88380508 | Metastatic epidural spinal cord compression |
| Q38783252 | Metastatic osteosarcoma: a challenging multidisciplinary treatment. |
| Q37809857 | Metastatic retropharyngeal lymph nodes in nasopharyngeal carcinoma: imaging criteria |
| Q38692839 | Metastatic soft tissue sarcoma: current treatment landscape and future perspectives. |
| Q96342724 | Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas? |
| Q100546431 | Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress |
| Q33382465 | MicroRNA-221 and -222 pathway controls melanoma progression |
| Q38841996 | MicroRNAs in non-small cell lung cancer invasion and metastasis: from the perspective of the radiation oncologist |
| Q92014825 | Microsatellite instability and mismatch repair deficiency in the era of precision immuno-oncology |
| Q88510360 | Might robotic-assisted surgery become commonplace in endometrial cancer treatment? |
| Q38020239 | Minimally invasive cystectomy approaches in the treatment of bladder cancer. |
| Q78380603 | Minimally invasive procedure and robotic technology combined to treat prostate cancer |
| Q84071363 | Minimally invasive surgery for colorectal cancer |
| Q90988852 | Minimally invasive surgery for pancreatic cancer |
| Q37546060 | Minimally invasive surgery for renal cell carcinoma |
| Q37183470 | Minimally invasive surgical modalities in the management of localized prostate cancer |
| Q89464135 | Minimizing residual occult nodal metastasis in NSCLC: recent advances, current status and controversies |
| Q47586547 | Minimizing toxicity in breast irradiation |
| Q37982443 | Minimizing toxicity in early-stage testicular cancer treatment |
| Q49997371 | Minimum unit pricing for alcohol: the most cost-effective of cancer prevention strategies? |
| Q34734285 | Mismatch repair defects as a cause of resistance to cytotoxic drugs |
| Q37483987 | Mode of action and clinical impact of VEGF signaling inhibitors |
| Q93149599 | Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy |
| Q37909363 | Mohs surgery for melanoma: rationale, advances and possibilities. |
| Q37300040 | Molecular abnormalities in Ewing's sarcoma |
| Q34734178 | Molecular and pharmacological strategies to overcome multidrug resistance |
| Q39433258 | Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics |
| Q37788246 | Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications |
| Q34734258 | Molecular biomarkers in HNSCC: prognostic and therapeutic implications |
| Q24649880 | Molecular breast imaging |
| Q37614592 | Molecular changes in pancreatic cancer |
| Q92730798 | Molecular characteristics of testicular germ cell tumors: pathogenesis and mechanisms of therapy resistance |
| Q37183447 | Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities |
| Q92014834 | Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors |
| Q38189444 | Molecular imaging for the characterization of breast tumors. |
| Q37025942 | Molecular markers for bladder cancer: the road to a multimarker approach |
| Q36788481 | Molecular markers of chemotherapeutic response and toxicity in colorectal cancer |
| Q37982453 | Molecular mechanisms of cisplatin resistance in bladder cancer. |
| Q37159537 | Molecular mechanisms of head and neck cancer |
| Q38010801 | Molecular mechanisms of temozolomide resistance in glioblastoma multiforme |
| Q35576159 | Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways |
| Q35641225 | Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis |
| Q35918449 | Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness |
| Q36066191 | Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway |
| Q36118431 | Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle |
| Q37183461 | Molecular pathology and potential therapeutic targets in soft-tissue sarcoma |
| Q38156191 | Molecular pathways and potential therapeutic targets in glioblastoma multiforme |
| Q36788498 | Molecular predictors of chemotherapy response in non-small-cell lung cancer |
| Q38539422 | Molecular profiling of gliomas: potential therapeutic implications. |
| Q37598935 | Molecular profiling of laryngeal cancer |
| Q37894668 | Molecular signatures that predict nodal metastasis in bladder cancer: does the primary tumor tell tales? |
| Q33306116 | Molecular staging for patients with malignant melanoma |
| Q86342827 | Molecular targets in cancer therapy |
| Q36927065 | Molecular targets in melanoma: time for 'ethnic personalization' |
| Q35782919 | Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. |
| Q80154604 | Molecular therapeutic targets for bladder cancer |
| Q96681814 | Molecular therapeutic targets in non-small cell lung cancer |
| Q37483949 | Molecular-targeted therapy in malignant melanoma |
| Q36817109 | Molecularly targeted therapies for malignant gliomas: advances and challenges |
| Q36334896 | Molecularly targeted therapy in renal cell carcinoma |
| Q36689144 | Molecularly targeted therapy in renal cell carcinoma: where do we go from here? |
| Q38153444 | Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer |
| Q100536472 | Monoclonal antibodies as an addition to current myeloma therapy strategies |
| Q36613987 | Monoclonal antibodies in chronic lymphocytic leukemia |
| Q36066157 | Monoclonal antibody therapy of ovarian cancer |
| Q35987734 | Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. |
| Q36842747 | Motexafin gadolinium: a novel radiosensitizer for brain tumors. |
| Q37845835 | Motherhood after breast cancer: searching for la dolce vita. |
| Q38245669 | Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer |
| Q84797216 | Multidisciplinary management of childhood sarcoma: time to expand |
| Q37300020 | Multidisciplinary management of resectable adenocarcinoma of the pancreatic head |
| Q79308863 | Multidisciplinary teamwork in urological oncology |
| Q36636630 | Multidisciplinary treatment of patients with hepatocellular carcinoma |
| Q36974685 | Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges |
| Q57142675 | Multifunctional nanoparticles for prostate cancer therapy |
| Q37782087 | Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks |
| Q38002470 | Multimodal treatment strategies for locally advanced rectal cancer |
| Q37025935 | Multimodality management of brain metastases in metastatic melanoma patients. |
| Q35641236 | Multimodality therapy for cancers of the esophagus and gastric cardia |
| Q37338260 | Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction |
| Q35034832 | Multimodality treatment of metastatic renal cell carcinoma |
| Q50047929 | Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches |
| Q45924070 | Multimodality treatment of two cases of intracardiac leiomyomatosis with enormous mass in the abdominopelvic cavity. |
| Q37508012 | Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents |
| Q36118436 | Multiple myeloma: an update of developments in targeted therapy |
| Q84962651 | Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer |
| Q34996698 | Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. |
| Q96031023 | Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years |
| Q42695934 | NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype? |
| Q36879127 | Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy |
| Q38625186 | Nab-paclitaxel in patients with metastatic melanoma |
| Q34891444 | Nano- and microrobotics: how far is the reality? |
| Q38797818 | Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer |
| Q36253332 | Nanostructured lipid carriers loaded with tributyrin as an alternative to improve anticancer activity of all-trans retinoic acid. |
| Q36842770 | Nanotechnology for targeted cancer therapy |
| Q34662481 | Nanotube x-ray for cancer therapy: a compact microbeam radiation therapy system for brain tumor treatment |
| Q37705415 | Nasopharyngeal carcinoma: alternative treatment options after disease progression |
| Q36974673 | National quality validation programs for breast centers |
| Q38664945 | Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls. |
| Q36974680 | Need for a paradigm shift in cancer prevention and clinical oncology |
| Q38020243 | Neoadjuvant and adjuvant treatment of renal cell carcinoma |
| Q37909365 | Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions |
| Q36842791 | Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer. |
| Q38592163 | Neoadjuvant chemotherapy in cervical cancer: an update |
| Q34733951 | Neoadjuvant chemotherapy in early-stage non-small cell lung cancer |
| Q36334882 | Neoadjuvant chemotherapy in invasive bladder cancer |
| Q60221524 | Neoadjuvant chemotherapy in ovarian cancer |
| Q96429958 | Neoadjuvant therapy for muscle-invasive bladder cancer |
| Q37705424 | Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials |
| Q38068585 | Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives |
| Q93191103 | Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma |
| Q37508037 | Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer |
| Q84451522 | Nephron-sparing surgery versus radical nephrectomy for kidney tumors: benefits and limitations |
| Q38666768 | Neratinib for the treatment of HER2-positive early stage breast cancer. |
| Q99628330 | Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer |
| Q37118964 | Nerve-sparing techniques in open and laparoscopic prostatectomy. |
| Q126005028 | Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies |
| Q42809906 | Neuro-oncology, a decade of temozolomide and beyond |
| Q38096476 | Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy |
| Q38711101 | Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy |
| Q37449019 | New TNM classification for non-small-cell lung cancer |
| Q36411076 | New advances in focal therapy for early stage prostate cancer |
| Q34734156 | New agents for the treatment of renal cell carcinoma |
| Q91547900 | New and important changes in breast cancer TNM: incorporation of biologic factors into staging |
| Q35641203 | New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective |
| Q36817127 | New approaches in metastatic melanoma: biological and molecular targeted therapies |
| Q36879172 | New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. |
| Q33383640 | New approved dasatinib regimen available for clinical use. |
| Q37357304 | New avenues for second-line treatment of metastatic non-small-cell lung cancer |
| Q78721293 | New cancer drug designed to overcome drug-resistant cells |
| Q34734253 | New chemoradiotherapy combinations in head and neck cancer. |
| Q74450321 | New combination promising against colon cancer |
| Q38153442 | New concepts and insights into the role of radiation therapy in extracranial metastatic disease |
| Q36118413 | New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas |
| Q37952237 | New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre-SLNB). |
| Q55465496 | New developments in targeted molecular therapies for glioblastoma. |
| Q36691810 | New drug therapies for advanced renal cell carcinoma |
| Q37854715 | New drug therapies in peripheral T-cell lymphoma |
| Q53965373 | New drugs, new drug resistance mechanisms. |
| Q38300338 | New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer |
| Q47325809 | New frontiers in therapeutic resistance in cancer |
| Q36636660 | New horizons in multiple myeloma therapy |
| Q100297020 | New insights into ErbB3 function and therapeutic targeting in cancer |
| Q86450860 | New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer? |
| Q36424072 | New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy |
| Q53592596 | New insights into the molecular profile of lung adenocarcinoma and implications for therapy. |
| Q62991414 | New insights on personalized cancer treatments: a report from the ESMO Congress |
| Q51645023 | New investigations into the stability of Mesna using LC-MS/MS and NMR. |
| Q37577930 | New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma |
| Q48061067 | New molecular oncology-changing era: prospects and challenges of cancer genome and integrative systems biology |
| Q48440244 | New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology. |
| Q36532080 | New molecular targets in advanced prostate cancer |
| Q36118418 | New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response |
| Q33183924 | New perspectives for the diagnosis and treatment of oligodendroglioma. |
| Q36066144 | New standards in the chemotherapy of metastatic hormone-refractory prostate cancer |
| Q34733944 | New strategies in the treatment of resectable non-small cell lung cancer |
| Q74450335 | New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer |
| Q78380607 | New study expands look at effects of high-dose vitamin D with docetaxel for advanced prostate cancer patients |
| Q38598269 | New surgical approaches for clinically high-risk or metastatic prostate cancer |
| Q38002469 | New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies |
| Q51839566 | New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. |
| Q47432725 | New targets and therapies for gastrointestinal stromal tumors |
| Q36974703 | New targets for non-small-cell lung cancer therapy |
| Q38315779 | New therapies in non-Hodgkin lymphoma |
| Q78721275 | New treatment option for postmenopausal women with early breast cancer |
| Q79870195 | New treatment strategies for malignant gliomas |
| Q27001080 | New vitamin D analogs as potential therapeutics in melanoma |
| Q39012067 | Newer medical therapies for metastatic soft tissue sarcoma |
| Q56775607 | News in brief |
| Q38836121 | Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities |
| Q38552883 | Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer |
| Q38399753 | Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor |
| Q89133366 | Niraparib for the treatment of ovarian cancer |
| Q38575000 | Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma |
| Q40244187 | Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study |
| Q38636284 | Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab |
| Q88788617 | Nivolumab for the treatment of colorectal cancer |
| Q57283779 | Nivolumab for the treatment of hepatocellular carcinoma |
| Q47715425 | Nivolumab for the treatment of urothelial cancers |
| Q38592160 | Nivolumab in combination with ipilimumab for the treatment of melanoma |
| Q38989508 | Nivolumab in melanoma |
| Q52645578 | Nivolumab in squamous cell carcinoma of the head and neck. |
| Q38241095 | No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide |
| Q37774355 | No cookie-cutter oncology: individualized treatment approaches for women with corpus endometrial cancer |
| Q36407441 | Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals |
| Q96167779 | Non-metastatic castration-resistant prostate cancer: current status and future directions |
| Q30238815 | Non-visible asymptomatic haematuria: a review of the guidelines from the urologist's perspective |
| Q35739676 | Nonhistone protein acetylation as cancer therapy targets |
| Q34969252 | Noninterferon-based adjuvant therapy for high-risk melanoma |
| Q38286089 | Noninvasive approaches for detecting and monitoring bladder cancer |
| Q35918466 | Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy |
| Q37411182 | Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. |
| Q36500541 | Nonplatinum therapy in advanced bladder cancer |
| Q34733987 | Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy |
| Q36752048 | Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies |
| Q36397832 | Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy |
| Q37866784 | Notch signaling in lung cancer |
| Q28282794 | Novel advances in pancreatic cancer treatment |
| Q37614590 | Novel agents for the treatment of adenocarcinoma of the pancreas |
| Q39290199 | Novel agents in mantle cell lymphoma |
| Q83198381 | Novel agents target existing tumor vasculature |
| Q37385373 | Novel anti-tubulin cytotoxic agents for breast cancer |
| Q38020248 | Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value |
| Q99355533 | Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer |
| Q38500371 | Novel approaches to pediatric leukemia treatment |
| Q38055491 | Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia |
| Q36817132 | Novel inhibitors in the treatment of metastatic melanoma |
| Q51585501 | Novel molecular trends in the management of advanced non-small-cell lung cancer. |
| Q36817140 | Novel small-molecule therapy of Hodgkin lymphoma |
| Q36995686 | Novel strategies for treating relapsed/refractory urothelial carcinoma |
| Q34734131 | Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer |
| Q92427015 | Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine |
| Q37782097 | Novel targeted therapies in the treatment of soft-tissue sarcomas |
| Q37449063 | Novel therapeutic agents for osteosarcoma |
| Q93047059 | Novel therapeutic targets for cancer metastasis |
| Q37508041 | Novel therapeutics for melanoma |
| Q37508027 | Novel therapeutics for patients with non-muscle-invasive bladder cancer |
| Q35728742 | Novel therapies for patients with chronic myeloid leukemia |
| Q35782940 | Novel therapies for recurrent ovarian cancer management |
| Q44342789 | Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers |
| Q37546045 | Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy |
| Q38220335 | Novel treatment options in stage I non-small-cell lung cancer |
| Q98773837 | Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma |
| Q74450438 | Novuspharma announces preliminary results of phase II trials for BBR 3464 |
| Q37256821 | Nuclear medicine in the management of thyroid disease |
| Q38592165 | Nuclear protein in testis midline carcinoma with unusual elevation of α-fetoprotein and synaptophysin positivity: a case report and review of the literature |
| Q38264784 | Nutrition and prostate cancer: an overview |
| Q26796568 | ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer |
| Q74450496 | OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva |
| Q37546055 | Obesity and renal cell carcinoma: epidemiology, underlying mechanisms and management considerations |
| Q37845824 | Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia |
| Q57112150 | Olaparib for the treatment of breast cancer |
| Q90856051 | Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation |
| Q47729241 | Olaratumab for the treatment of advanced soft tissue sarcoma |
| Q84942415 | Omega-3 fatty acids: a potential booster for tamoxifen therapy? |
| Q100306437 | On the road to treatment-free remission in chronic myeloid leukemia: what about "the others"? |
| Q53718852 | On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis? |
| Q87011809 | Onartuzumab in lung cancer: the fall of Icarus? |
| Q36605354 | Oncogenesis and mutagenesis of pituitary tumors |
| Q35611901 | Oncogenomics: prospects for the future |
| Q92648582 | Oncologic therapies associated with cardiac toxicities: how to minimize the risks |
| Q36499227 | Oncolytic adenoviruses as antiglioma agents |
| Q36668242 | Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas |
| Q37300008 | Oncolytic viruses: a novel form of immunotherapy |
| Q74450679 | Oncolytics Biotech releases REOLYSIN phase I clinical trial results |
| Q36950507 | Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer? |
| Q50851021 | Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently? |
| Q35918462 | Optical imaging of mice in oncologic research |
| Q79620027 | Optimal approach to potentially resectable liver metastases from colorectal cancer |
| Q88552121 | Optimal design and endpoint of clinical trials using immune checkpoint blocking agents |
| Q38168925 | Optimal management of elderly patients with myeloma |
| Q38620407 | Optimal management of low-risk gestational trophoblastic neoplasia |
| Q87285875 | Optimal management of primary retroperitoneal sarcoma: an update |
| Q37945641 | Optimal management of pulmonary metastases from colorectal cancer |
| Q38545533 | Optimal management of resectable gastric adenocarcinoma |
| Q38194594 | Optimal management of sarcomas of the breast: an update. |
| Q38225033 | Optimal management of squamous cell carcinoma of the anal canal: where are we now? |
| Q43173702 | Optimal management of uterine leiomyosarcoma |
| Q38526456 | Optimal sequence of bone target drugs in metastatic prostatic cancer |
| Q37642804 | Optimal surgery for advanced gastric cancer |
| Q35070425 | Optimal therapy and management of endometrial cancer |
| Q34674007 | Optimal therapy for desmoid tumors: current options and challenges for the future |
| Q38664897 | Optimal therapy for resectable rectal cancer |
| Q39813009 | Optimal timing of radical cystectomy in T1 high-grade bladder cancer |
| Q36499255 | Optimal treatment of metastatic colorectal cancer |
| Q38624864 | Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents |
| Q37931905 | Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors |
| Q90988873 | Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia |
| Q38048822 | Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma |
| Q36381276 | Optimizing locoregional control and survival for women with breast cancer: a review of current developments in postmastectomy radiotherapy |
| Q37159513 | Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients |
| Q37628698 | Optimizing regional infusion treatment strategies for melanoma of the extremities |
| Q80273848 | Optimizing the delivery of cancer care |
| Q37960915 | Optimizing treatment for metastatic renal cell carcinoma |
| Q47549019 | Optimizing treatment in recurrent epithelial ovarian cancer |
| Q37866796 | Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action |
| Q56889472 | Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma |
| Q38818969 | Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: What is the role for surgery? |
| Q90735255 | Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route |
| Q34216239 | Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. |
| Q38640514 | Oral ixazomib maintenance therapy in multiple myeloma. |
| Q38356369 | Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients |
| Q60473028 | Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review |
| Q35034820 | Organ preservation strategies in bladder cancer |
| Q37642783 | Organ-sparing strategies in the management of invasive bladder cancer |
| Q37183466 | Orthopedic surgery implications of breast cancer |
| Q98285216 | Osteolytic metastasis in breast cancer: effective prevention strategies |
| Q37577926 | Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients |
| Q36842773 | Outcomes and prognosis in advanced renal cell carcinoma |
| Q37782094 | Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly |
| Q45027102 | Outcomes in unresectable and locally advanced resected cholangiocarcinoma |
| Q38251243 | Outcomes of xerostomia-related quality of life for nasopharyngeal carcinoma treated by IMRT: based on the EORTC QLQ-C30 and H&N35 questionnaires |
| Q98476370 | Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma |
| Q38665438 | Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. |
| Q38068586 | Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition |
| Q38081239 | Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways |
| Q38682189 | Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms |
| Q30238693 | Overview and recent advances in the treatment of neuroblastoma |
| Q38081244 | Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer |
| Q37242664 | Oxaliplatin-based chemotherapy in the management of colorectal cancer |
| Q37845832 | Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors |
| Q38223511 | P95 HER2 fragments and breast cancer outcome |
| Q99554514 | PARP inhibition in treatment of pancreatic cancer |
| Q88451674 | PARP inhibitors and stratified treatment of prostate cancer |
| Q96293461 | PARP inhibitors in prostate cancer: time to narrow patient selection? |
| Q60997165 | PD-1 blockade: promoting endogenous anti-tumor immunity |
| Q37357297 | PET and PET-CT imaging of gynecological malignancies: present role and future promise |
| Q37732292 | PET and PET-CT in radiation treatment planning for lung cancer |
| Q37909361 | PET and PET/CT in radiation treatment planning for prostate cancer |
| Q33578187 | PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed |
| Q38608555 | PET-directed therapy in Hodgkin lymphoma: Ready for prime time? |
| Q38202189 | PET/CT in therapy evaluation of patients with lung cancer |
| Q38259259 | PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? |
| Q54603099 | PLX4032 and melanoma: resistance, expectations and uncertainty. |
| Q53560105 | Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer. |
| Q36118375 | Paclitaxel for AIDS-associated Kaposi's sarcoma. |
| Q36788450 | Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer |
| Q37705421 | Pain management in multiple myeloma. |
| Q96436757 | Palliative care for advanced gastric cancer |
| Q92403590 | Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects |
| Q37845831 | Palliative therapy for osteosarcoma. |
| Q37732289 | Palliative thoracic radiotherapy for lung cancer |
| Q37038922 | Palliative treatment of poor prognosis patients with malignant gliomas |
| Q38132238 | Palonosetron for the prevention of chemotherapy-induced nausea and vomiting |
| Q37687368 | Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. |
| Q38592167 | Pancreatic cancer: BRCA mutation and personalized treatment |
| Q33863875 | Pancreatic cancer: current standards, working towards a new therapeutic approach |
| Q38212152 | Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma |
| Q36879141 | Panitumumab in colorectal cancer |
| Q38117191 | Panitumumab in metastatic colorectal cancer. |
| Q42656995 | Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer |
| Q38519497 | Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma |
| Q36689139 | Partial nephrectomy achieves local tumor control and prevents chronic kidney disease |
| Q36731409 | Partial-breast irradiation: towards a replacement for whole-breast irradiation? |
| Q35070435 | Past, current and future protocols for combined modality therapy in childhood medulloblastoma |
| Q38664687 | Pathobiology of pancreatic cancer: implications on therapy |
| Q38010799 | Pathogenesis and management of primary CNS lymphoma |
| Q38062022 | Pathways and targets in hepatocellular carcinoma |
| Q99545259 | Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma |
| Q37732294 | Patient-based strategy for systemic treatment of metastatic renal cell carcinoma |
| Q38205466 | Patient-reported outcomes after neoadjuvant therapy for rectal cancer: a systematic review. |
| Q57138592 | Patient-reported outcomes in ovarian cancer: are they key factors for decision making? |
| Q36842777 | Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection |
| Q38571120 | Pazopanib in ovarian cancer |
| Q28269229 | Pazopanib in the treatment of soft tissue sarcoma |
| Q37752357 | Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma |
| Q37809864 | Peculiar features and tailored management of adult cancers occurring in pediatric age. |
| Q37988570 | Pediatric acute myeloid leukemia |
| Q74450471 | Pediatric leukemia in the new millennium |
| Q101041917 | Pediatric relapsed acute myeloid leukemia: a systematic review |
| Q36235531 | Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy |
| Q37118928 | Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. |
| Q100523015 | Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic merkel cell carcinoma: safety and efficacy |
| Q102052277 | Pembrolizumab for advanced cervical cancer: safety and efficacy |
| Q38640518 | Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer |
| Q49036770 | Pembrolizumab for the treatment of bladder cancer |
| Q57036372 | Pembrolizumab for the treatment of gastric cancer |
| Q39198286 | Pembrolizumab for the treatment of non-small cell lung cancer. |
| Q99545258 | Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy |
| Q102052271 | Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy |
| Q35782906 | Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma |
| Q35117722 | Pemetrexed (Alimta®): a novel multitargeted antifolate agent |
| Q35003631 | Pemetrexed for the treatment of non-small-cell lung cancer |
| Q36817105 | Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial |
| Q36118385 | Pemetrexed-cisplatin combination in mesothelioma |
| Q34734085 | Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). |
| Q35843663 | Pemetrexed: a novel antifolate agent enters clinical practice |
| Q35641196 | Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia |
| Q74450410 | Pentostatin effective as preparative regimen for kidney transplants |
| Q36689136 | Percutaneous radiofrequency ablation: minimally invasive therapy for renal tumors |
| Q91106455 | Percutaneous renal mass biopsy: historical perspective, current status, and future considerations |
| Q37988567 | Perineural invasion and spread in head and neck cancer |
| Q37931891 | Perioperative irradiation in extremity soft tissue sarcoma |
| Q36334874 | Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma |
| Q37256815 | Peripheral thyrotropin receptor mRNA as a novel marker for differentiated thyroid cancer diagnosis and surveillance |
| Q47309343 | Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment. |
| Q36118424 | Personalized medical treatment strategies for patients with chronic myeloid leukemia |
| Q37799826 | Personalized medicine for non-small-cell lung cancer. |
| Q39946469 | Personalizing cancer care: updates on head and neck cancer |
| Q51698938 | Personalizing prophylactic surgery in cancer: current practice and future perspectives from new genome-wide association studies. |
| Q38386811 | Personalizing surgical margins in retroperitoneal sarcomas |
| Q92496246 | Personalizing surgical margins in retroperitoneal sarcomas: an update |
| Q43275322 | Personalizing therapy for metastatic breast cancer |
| Q36788467 | Perspectives of clinical proteomics in gastrointestinal cancer |
| Q36668271 | Perspectives of proteomics in acute myeloid leukemia |
| Q92452462 | Pertuzumab for the treatment of breast cancer |
| Q38132237 | Pertuzumab for the treatment of metastatic breast cancer |
| Q38286163 | Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer |
| Q35204965 | Peutz-Jeghers syndrome: genetic screening |
| Q91983391 | Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy |
| Q74450392 | Pharmacia's SU5416 not effective |
| Q34733994 | Pharmacogenetics of cytotoxic drugs |
| Q78380611 | Phase I trial of novel HER-2 vaccine for breast cancer initiated |
| Q74450351 | Phase II clinical trial of XYOTAX in non-small cell lung cancer to continue |
| Q37705422 | Phase II clinical trials in oncology: are we hitting the target? |
| Q34734143 | Photodynamic therapy for superficial bladder cancer |
| Q36284494 | Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer |
| Q37030808 | Photon radiotherapy for the treatment of high-grade gliomas |
| Q39402117 | Phthalocyanine induced phototherapy coupled with Doxorubicin; a promising novel treatment for breast cancer |
| Q51160791 | Pioneering the trail of cancer immunotherapy. |
| Q90341547 | Pitfalls and controversies in pathology impacting breast cancer management |
| Q37483999 | Placental ischemia and breast cancer risk after preeclampsia: tying the knot |
| Q38787315 | Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles |
| Q37799831 | Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes |
| Q110698403 | Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer |
| Q88693185 | Pocket colposcope: could it improve attendance and increase access to cervical cancer screening programmes? |
| Q37909373 | Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies |
| Q37774359 | Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy |
| Q34734060 | Polycythemia vera: diagnosis and treatment 2002. |
| Q30802505 | Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data |
| Q96809587 | Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies |
| Q36532097 | Positron emission tomography in gynecological malignancies |
| Q36334917 | Positron emission tomography: clinical applications in oncology. Part 1. |
| Q36448703 | Positron emission tomography: clinical applications in oncology. Part 2. |
| Q51444618 | Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil. |
| Q47966425 | Post-prostatectomy radiation therapy for locally recurrent prostate cancer |
| Q36284519 | Postchemotherapy residual masses in advanced seminoma: current management and outcomes. |
| Q37821901 | Postchemotherapy retroperitoneal lymph node dissection for testis cancer |
| Q53300033 | Postoperative nodal irradiation in breast cancer patients with 1 to 3 axillary lymph nodes involved: the debate continues…. |
| Q46188672 | Postoperative stereotactic radiosurgery for limited brain metastases: are we ready for prime time? |
| Q81055569 | Potential new drug targets against hormone-dependent breast cancer identified |
| Q37866794 | Potential of CXCR4 antagonists for the treatment of metastatic lung cancer |
| Q34969287 | Potential of DMXAA combination therapy for solid tumors |
| Q37894688 | Potential of histone deacetylase inhibitors for bladder cancer treatment |
| Q62778275 | Potential of imaging biomarkers for characterization of renal masses |
| Q33538825 | Potential of optical coherence tomography for early diagnosis of oral malignancies |
| Q37008860 | Potential of urinary biomarkers in early bladder cancer diagnosis |
| Q36797201 | Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML |
| Q55463671 | Potential role of miRNAs and their inhibitors in glioma treatment |
| Q37866785 | Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer |
| Q36532110 | Potential use of humanized antibodies in the treatment of breast cancer. |
| Q38263711 | Precision medicine for prostate cancer |
| Q37809859 | Predicting and preventing melanoma invasiveness: advances in clarifying E2F1 function |
| Q104566325 | Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review |
| Q84861584 | Predicting response to IL-2 therapy for metastatic melanoma |
| Q36788485 | Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. |
| Q34022135 | Predicting response to neoadjuvant therapy in esophageal cancer. |
| Q34257190 | Predicting survival in chronic lymphocytic leukemia |
| Q42393839 | Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key? |
| Q30446429 | Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis |
| Q37873473 | Predictive and prognostic factors for gliomas |
| Q39170872 | Predictive biomarkers along gastric cancer pathogenetic pathways |
| Q93047071 | Predictive biomarkers of response to immune checkpoint inhibitors in melanoma |
| Q37934964 | Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease |
| Q54578801 | Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. |
| Q37854712 | Predictive markers and driving factors behind Richter syndrome development |
| Q45116753 | Predictive modeling in cancer: where systems biology meets the stock market. |
| Q37821905 | Predictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer |
| Q47583693 | Pregnancy and live birth after successful cancer treatment in young women: the need to improve fertility preservation and advice for female cancer patients |
| Q36235586 | Preoperative and adjuvant therapies for upper gastrointestinal cancers |
| Q31043603 | Present and potential future issues in glioblastoma treatment |
| Q34734273 | Present status of management of nasopharyngeal carcinoma |
| Q91469961 | Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas |
| Q36691815 | Presurgical therapy in metastatic renal cell carcinoma |
| Q57129460 | Preventing central nervous system metastases in non-small cell lung cancer |
| Q38917015 | Preventing recurrence of diffuse malignant peritoneal mesothelioma |
| Q80273831 | Prevention |
| Q37449048 | Prevention, chemoradiation and surgery for anal cancer. |
| Q38123205 | Prevention, identification and treatment of vulvar squamous (pre)malignancies: a review focusing on quality of care |
| Q80307106 | Primary CNS lymphoma |
| Q37799825 | Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer |
| Q36668251 | Primary gastrointestinal tract lymphoma: diagnosis and management of common neoplasms |
| Q38062554 | Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. |
| Q38048814 | Primary systemic therapy in HER2-amplified breast cancer: a clinical review |
| Q38168926 | Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer? |
| Q91767064 | Prodrugs for targeted cancer therapy |
| Q91322762 | Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies |
| Q53693389 | Prognostic biomarkers for cholangiocarcinoma and their clinical implications. |
| Q34733963 | Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy |
| Q34734166 | Prognostic factors and molecular markers for renal cell carcinoma |
| Q36118398 | Prognostic factors for breast cancer and their use in the clinical setting |
| Q37782089 | Prognostic factors for local recurrence following breast-conserving treatment in young women |
| Q91250745 | Prognostic factors for uterine adenosarcoma: a review |
| Q38196855 | Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents |
| Q80714181 | Prognostic factors in soft-tissue sarcomas: what have we learnt? |
| Q38462720 | Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy |
| Q37687395 | Prognostic markers in osteosarcoma |
| Q86342843 | Prognostic relevance of nutritional status in patients with advanced esophageal cancer |
| Q37945638 | Prognostic significance of tumor budding in gastrointestinal tumors. |
| Q82623341 | Prognostic value of CA 125 in transitional cell carcinoma of the bladder |
| Q37982445 | Prognostic value of circulating tumor cells in primary and metastatic breast cancer |
| Q78721322 | Prognostic value of p53 overexpression in bladder tumors treated with Bacillus Calmette-Guerin |
| Q47629558 | Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization |
| Q38438248 | Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer |
| Q44412336 | Prognostication in Merkel cell carcinoma |
| Q37134442 | Progress and challenges in the adjuvant treatment of stage II and III colon cancers |
| Q35160205 | Progress and perspectives in chemoprevention of head and neck cancer |
| Q90457622 | Progress in determining response to treatment in gastrointestinal stromal tumor |
| Q87403371 | Progress in pancreatic cancer: moving beyond gemcitabine? |
| Q35576191 | Progress in the medical treatment of advanced colorectal cancer |
| Q37934958 | Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial |
| Q38283828 | Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial |
| Q37982449 | Progress of oncolytic viruses in sarcomas |
| Q83903356 | Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer |
| Q37004695 | Progression of endocrine therapies for breast cancer: where are we headed? |
| Q88600603 | Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer |
| Q36605350 | Prolactin-secreting tumors: what's new? |
| Q82787449 | Promise of antisense oligodeoxynucleotide-based therapy for bladder cancer |
| Q83073984 | Promises and challenges of human papillomavirus vaccines for cervical cancer |
| Q36235591 | Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity |
| Q101161388 | Promising novel therapies for relapsed and refractory testicular germ cell tumors |
| Q98878468 | Promising predictors of checkpoint inhibitor response in NSCLC |
| Q74450413 | Promising results for Arimidex and Femara |
| Q38002472 | Prophylactic cranial irradiation for small-cell lung cancer: how, when and for whom? |
| Q50141660 | Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial? |
| Q89005790 | Proposed use of self-regulating temperature nanoparticles for cancer therapy |
| Q37483993 | Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms |
| Q35204961 | Prospects for colorectal cancer treatment: oral chemotherapy and targeted biotherapy |
| Q37118956 | Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer |
| Q64987050 | Prospects of targeted and immune therapies in SCLC. |
| Q42063506 | Prostate cancer organoids: a potential new tool for testing drug sensitivity |
| Q53401041 | Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. |
| Q51016999 | Prostate cancer. Foreword. |
| Q38786316 | Prostate cancer: from Gleason scoring to prognostic grade grouping |
| Q90389831 | Prostate cancer: more effective use of underutilized postoperative radiation therapy |
| Q37183475 | Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention |
| Q99252768 | Prostate re-irradiation: current concerns and future perspectives |
| Q54469454 | Prostate stem cell antigen - novel biomarker and therapeutic target? |
| Q38168921 | Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications |
| Q36879159 | Prostate-sparing cystectomy: has Pandora's box been opened? |
| Q38259244 | Prostate-specific antigen screening, why have the guidelines changed? |
| Q37008876 | Prostatic transitional cell carcinoma: pathologic features and clinical management |
| Q36185620 | Proteasome inhibition as a therapeutic strategy for hematologic malignancies |
| Q74450416 | Proteasome inhibitor holds promise for patients with refractory multiple myeloma |
| Q38088003 | Proteasome inhibitors in acute leukemia. |
| Q86342895 | Proteasome inhibitors in the treatment of multiple myeloma |
| Q36448671 | Protective effects of green tea against prostate cancer |
| Q36334907 | Protective effects of tea polyphenols and caffeine |
| Q74450361 | Protein design labs begins Phase I trial of Remitogen in cancer patients with solid tumors |
| Q36381266 | Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery? |
| Q37377802 | Protein kinase D isoforms: new targets for therapy in invasive breast cancers? |
| Q38616345 | Proton beam therapy for hepatocellular carcinoma |
| Q101055259 | Proton therapy for thoracic malignancies: a review of oncologic outcomes |
| Q50781062 | Psychotherapy and psychopharmacology for mental health in adolescents with cancer: what integration is possible? |
| Q37038880 | Pure and robotic-assisted laparoscopic radical prostatectomy: technology and techniques merge to improve outcomes |
| Q35576196 | Pyrimidine nucleoside analogs in cancer treatment. |
| Q38389751 | Quality evaluation of randomized controlled trials reports of laparoscopy compared with open colorectal resection for colorectal cancer |
| Q38827992 | Quality indicators for thyroid cancer surgery: current perspective |
| Q90915283 | Quality measures improving endoscopic screening of colorectal cancer: a review of the literature |
| Q37945637 | Quality of RCTs exploring Helicobacter pylori eradication for the prevention of gastric cancer and preneoplastic lesions |
| Q37008863 | Quality of life and adjuvant systemic therapy for early-stage breast cancer |
| Q81346005 | Quality of life in head and neck cancer patients |
| Q34733977 | Quality of life in patients with cancers of the upper gastrointestinal tract |
| Q38265835 | Quality of life measures in soft tissue sarcoma |
| Q38096481 | Quality of reporting and its correlates among randomized controlled trials on acupuncture for cancer pain: application of the CONSORT 2010 Statement and STRICTA. |
| Q37894671 | Quality of reporting in randomized controlled trials conducted in China on the treatment of cancer pain |
| Q37788237 | Quality of voice after radiotherapy in early vocal cord cancer |
| Q37705409 | Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer |
| Q37134454 | RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer |
| Q37357300 | RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells |
| Q38002468 | ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway |
| Q104563798 | Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives |
| Q37614598 | Radiation therapy for intrahepatic malignancies |
| Q36573850 | Radiation therapy for retroperitoneal sarcoma |
| Q35728753 | Radiation-guided drug delivery systems |
| Q38176436 | Radical cystectomy and the implications of comorbidity |
| Q30240141 | Radical cystectomy: do we need standardization? |
| Q36381294 | Radical radiotherapy for urinary bladder cancer: treatment outcomes |
| Q86700708 | Radical versus partial nephrectomy for a small renal mass: does saving nephrons save lives? |
| Q84721700 | Radiochemotherapy in lung cancer: from reality to reality |
| Q37614569 | Radiochemotherapy in small-cell lung cancer |
| Q37614574 | Radiochemotherapy in the elderly with lung cancer. |
| Q35641212 | Radiofrequency ablation of small renal tumors |
| Q74450402 | Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment |
| Q34734238 | Radiolabeled immunoglobulin therapy: old barriers and new opportunities |
| Q35089123 | Radiologic screening for lung cancer |
| Q102215181 | Radiomics features as predictive and prognostic biomarkers in NSCLC |
| Q35611899 | Radiosurgery in the treatment of malignant brain tumors |
| Q38918333 | Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases |
| Q36407464 | Radiotherapeutic management of locally advanced head and neck cancer |
| Q95825926 | Radiotherapy |
| Q38030597 | Radiotherapy following radical prostatectomy |
| Q37788244 | Radiotherapy for laryngeal squamous cell carcinoma: current standards |
| Q37752373 | Radiotherapy for metastatic bone disease: current standards and future prospectus |
| Q37030790 | Radiotherapy for pediatric brain tumors: when and how. |
| Q36974690 | Radiotherapy in gastric cancer: a systematic review of literature and new perspectives. |
| Q96581917 | Radiotherapy in the era of COVID-19 |
| Q38467379 | Radiotherapy treatment for nonmelanoma skin cancer |
| Q38010805 | Radiotherapy-induced hypopituitarism: a review |
| Q38306050 | Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. |
| Q35843668 | Raloxifene and its role in breast cancer prevention |
| Q34734192 | Raloxifene for the treatment and prevention of breast cancer? |
| Q37945636 | Raltitrexed in mesothelioma |
| Q38513056 | Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma |
| Q46466221 | Rare subtypes of adenocarcinoma of the lung |
| Q35204936 | Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies |
| Q43499043 | Rational cotargeting of Pim-1 and Akt in prostate cancer. |
| Q81777537 | Rational targeting of Notch signaling in breast cancer |
| Q46528648 | Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma |
| Q37316983 | Reactive oxygen species: an Achilles' heel of melanoma? |
| Q55461220 | Real-time image guidance for brain tumor surgery through stimulated Raman scattering microscopy. |
| Q99545283 | Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma |
| Q95646502 | Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan |
| Q38577917 | Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure |
| Q39454057 | Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review |
| Q47567640 | Recent advances in fertility preservation and counseling for female cancer patients |
| Q38683954 | Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer |
| Q52665438 | Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. |
| Q35117729 | Recent advances in systemic therapy of soft tissue sarcomas |
| Q40143039 | Recent advances in targeted advanced lung cancer therapy in the elderly |
| Q35034840 | Recent advances in the field of tubulin polymerization inhibitors |
| Q36731426 | Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. |
| Q50072347 | Recent advances in the management of pancreatic adenocarcinoma |
| Q34734334 | Recent advances in the management of squamous cell carcinoma of the head and neck |
| Q34733969 | Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors |
| Q34537216 | Recent advances in the prevention and treatment of skin cancer using photodynamic therapy |
| Q37411186 | Recent advances in the systemic treatment of metastatic papillary renal cancer |
| Q36334892 | Recent advances in the treatment of bladder cancer |
| Q36066174 | Recent advances in the treatment of testicular cancer |
| Q38030593 | Recent advances in urinary bladder cancer detection |
| Q92896609 | Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology |
| Q37598944 | Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. |
| Q87508846 | Recent developments in second and third line therapy of metastatic renal cell carcinoma |
| Q36636637 | Recent developments in the chemotherapeutic options for nonsmall cell lung cancer |
| Q36614005 | Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer |
| Q51876651 | Recent innovations in head and neck oncology: a report from the ICHNO. |
| Q34734247 | Recent progress in the pharmacotherapy of cancer pain |
| Q36448687 | Recent trends and future perspectives in isolated hepatic perfusion in the treatment of liver tumors |
| Q35782945 | Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma |
| Q38251141 | Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies |
| Q35576169 | Recommendations for the management of malignant gliomas in the elderly |
| Q38956231 | Recovery of urinary continence after radical prostatectomy |
| Q36668246 | Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates |
| Q37118936 | Recurrent head and neck cancer: current treatment and future prospects. |
| Q38140000 | Recurrent or refractory primary central nervous lymphoma: therapeutic considerations |
| Q91488708 | Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line |
| Q46652612 | Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial |
| Q37159533 | Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia |
| Q37385388 | Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors |
| Q36636623 | Refining the postmenopausal breast cancer treatment paradigm: the FACE trial |
| Q38055493 | Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma |
| Q38674803 | Regorafenib for the treatment of unresectable hepatocellular carcinoma. |
| Q27852864 | Regorafenib in metastatic colorectal cancer. |
| Q38096471 | Regorafenib: carving a niche in the crowded therapeutic landscape |
| Q36066149 | Regulation of androgen receptor signaling in prostate cancer |
| Q36448676 | Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer |
| Q38055496 | Reirradiation for recurrent head and neck cancer |
| Q84942418 | Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer |
| Q93098193 | Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities |
| Q30248354 | Renal cell cancer: overview of the current therapeutic landscape. |
| Q37812610 | Renal cell carcinoma in children and adolescents |
| Q74450398 | Researcher makes breakthrough in cancer research |
| Q38500269 | Resected gastric cancer with D2 dissection: advances in adjuvant chemoradiotherapy and radiotherapy techniques |
| Q99556259 | Response letter to the editor |
| Q84787105 | Response to Lammers and Witjes article: new developments in intravesical therapy for non-muscle-invasive bladder cancer |
| Q47367544 | Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases |
| Q49185712 | Retinoblastoma protein determines aggressiveness in triple-negative breast cancer |
| Q34734152 | Retinoids in the prevention of bladder cancer |
| Q95409082 | Retraction |
| Q36066152 | Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle |
| Q36407480 | Review of clinical radioimmunotherapy |
| Q36691825 | Review of image-guided radiation therapy |
| Q38168922 | Review of management issues in relapsed osteosarcoma |
| Q37982452 | Review of recent studies on interventions for cognitive deficits in patients with cancer |
| Q37338231 | Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer |
| Q36284521 | Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia |
| Q38101607 | Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. |
| Q38895216 | Rewiring the solid tumor epigenome for cancer therapy |
| Q49849559 | Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
| Q100757404 | Ribociclib plus fulvestrant in the treatment of breast cancer |
| Q37202768 | Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer |
| Q38723842 | Risk of cardiac death among cancer survivors in the United States: a SEER database analysis. |
| Q53809725 | Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. |
| Q35232357 | Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis |
| Q38199178 | Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. |
| Q38284400 | Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. |
| Q38494344 | Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. |
| Q36352077 | Risk of second cancers after radiotherapy for cervical cancer |
| Q44692841 | Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies |
| Q38349157 | Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis |
| Q35187896 | Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis |
| Q37788238 | Risk stratification in extranodal natural killer/T-cell lymphoma |
| Q92311695 | Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature |
| Q37873471 | Risk-adapted chemotherapy in childhood medulloblastoma |
| Q47552411 | Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy |
| Q35611848 | Rituximab (Rituxan/MabThera): the first decade (1993-2003). |
| Q37508007 | Rituximab and chemotherapy in diffuse large B-cell lymphoma |
| Q36752014 | Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma |
| Q36573823 | Rituximab for the treatment of diffuse large B-cell lymphomas |
| Q37799820 | Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia |
| Q34733916 | Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma |
| Q38255306 | Robotic and minimal access surgery: technology and surgical outcomes of radical prostatectomy for prostate cancer |
| Q51813455 | Robotic and open radical prostatectomy: is there reason to be receptive to change now and in the future? |
| Q36352056 | Robotic prostatectomy: a pooled analysis of published literature |
| Q81501626 | Robotic surgery: the coming of a new era in surgical innovation |
| Q51876500 | Robotic versus nonrobotic surgery: experts, toys and prostatectomy. |
| Q51543383 | Robotic-assisted laparoscopic prostatectomy: the ideal application for antegrade nerve-sparing prostatectomy. |
| Q36950489 | Robotic-assisted laparoscopic radical prostatectomy: a report of the current state |
| Q51489406 | Robotic-assisted partial nephrectomy: the next gold standard for the treatment of intracapsular renal tumors. |
| Q38030591 | Robotic-assisted radical cystectomy: current technique and outcomes |
| Q37752369 | Robotic-assisted radical prostatectomy in 2010. |
| Q40542547 | Rolapitant for the treatment of chemotherapy-induced nausea and vomiting |
| Q37642786 | Role and rationale of gene therapy and other novel therapies in the management of NMIBC. |
| Q33690816 | Role and value of diffusion-weighted MRI in the radiotherapeutic management of head and neck cancer. |
| Q37812611 | Role of C-reactive protein as a biomarker for renal cell carcinoma |
| Q35843677 | Role of FDG-PET in the diagnosis and management of lung cancer |
| Q35843694 | Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases |
| Q37449042 | Role of MRI for staging of rectal cancer |
| Q37159543 | Role of MRI in screening, diagnosis and management of breast cancer |
| Q36573847 | Role of PET/PET-CT in the management of sarcomas |
| Q35843713 | Role of TGF-beta in cancer and the potential for therapy and prevention |
| Q36185617 | Role of allogeneic stem cell transplantation in multiple myeloma |
| Q34734310 | Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma |
| Q37952235 | Role of bacillus Calmette-Guérin in the treatment of advanced melanoma |
| Q37965633 | Role of canonical Wnt signaling in endometrial carcinogenesis |
| Q35117717 | Role of capecitabine (Xeloda®) in breast cancer |
| Q37732285 | Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer |
| Q47423861 | Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. |
| Q36334921 | Role of chemotherapy in breast cancer |
| Q35728702 | Role of chemotherapy in patients with soft tissue sarcomas. |
| Q37183459 | Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas |
| Q36066178 | Role of chemotherapy in the management of epithelial ovarian cancer |
| Q34734126 | Role of chemotherapy in the management of ovarian cancer |
| Q37687389 | Role of chemotherapy in the management of soft tissue sarcomas |
| Q36605382 | Role of craniotomy in the management of pituitary adenomas and sellar/parasellar tumors |
| Q36613975 | Role of cytokines in head and neck squamous cell carcinoma |
| Q30378801 | Role of cytoreductive surgery in recurrent ovarian cancer. |
| Q34513604 | Role of efaproxiral in metastatic brain tumors |
| Q36499217 | Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors |
| Q37935772 | Role of everolimus in pancreatic neuroendocrine tumors |
| Q35918459 | Role of farnesyltransferase inhibitors in hematologic malignancies |
| Q34571439 | Role of fludarabine in hematological malignancies |
| Q37952234 | Role of fulvestrant in the management of postmenopausal breast cancer |
| Q33196126 | Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors |
| Q36689156 | Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia |
| Q37483982 | Role of intensity-modulated radiation therapy in gastrointestinal cancer |
| Q37449054 | Role of liver transplantation in the treatment of cholangiocarcinoma |
| Q38264776 | Role of miRNA in head and neck squamous cell carcinoma |
| Q37598941 | Role of nucleophosmin in acute myeloid leukemia. |
| Q57156236 | Role of omega-3 polyunsaturated fatty acids in preventing gastrointestinal cancers: current status and future perspectives |
| Q37483955 | Role of radiation therapy in the treatment of melanoma |
| Q30311915 | Role of resection for newly diagnosed malignant gliomas |
| Q37788241 | Role of sentinel lymph node biopsy in thyroid cancer |
| Q82324626 | Role of sorafenib in renal cell carcinoma: focus on elderly patients |
| Q35117753 | Role of systemic chemotherapy in metastatic cervical cancer |
| Q35204943 | Role of targeted therapy in non-small cell lung cancer: hype or hope? |
| Q37300004 | Role of thalidomide in previously untreated patients with multiple myeloma. |
| Q37202773 | Role of the prostaglandin pathway and the use of NSAIDs in genitourinary malignancies |
| Q37952242 | Role of tyrosine kinase inhibitors in the management of high-grade gliomas |
| Q33390876 | Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. |
| Q93052131 | Rucaparib in the landscape of PARP inhibition in ovarian cancer |
| Q33389563 | S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer? |
| Q92523257 | Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer |
| Q83461344 | Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer |
| Q36950466 | Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview |
| Q37909352 | Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer |
| Q37134463 | Salivary gland cancers: current treatments, molecular characteristics and new therapies |
| Q37934975 | Salivary gland sparing in the treatment of head and neck cancer |
| Q37256850 | Salvage laparoscopic surgery in advanced prostate cancer: is it possible or beneficial? |
| Q37338241 | Salvage of local recurrence after primary thermal ablation for small renal masses |
| Q103052017 | Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need |
| Q38101613 | Salvage treatment in prostate cancer: a clinical approach |
| Q37004657 | Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma |
| Q53292461 | Sapacitabine in the treatment of acute myeloid leukemia. |
| Q64039868 | Sarcomas of the breast |
| Q40059961 | Sarcomas of the head and neck in adult patients: current concepts and future perspectives |
| Q36532071 | Satraplatin: an orally available platinum analog for the treatment of cancer |
| Q38020242 | Schistosomiasis and bladder cancer: similarities and differences from urothelial cancer |
| Q79620021 | Screening and early diagnosis in lung cancer |
| Q30244651 | Screening and surveillance for hepatocellular carcinoma: perspective of a new era? |
| Q61925529 | Screening for ovarian cancer |
| Q38069188 | Screening for prostate cancer: an updated review. |
| Q47902314 | Screening of colorectal cancer: present and future. |
| Q38264330 | Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review. |
| Q38101609 | Second surgery for recurrent glioblastoma: advantages and pitfalls |
| Q73841227 | Second-line chemotherapy for non-small cell lung cancer |
| Q83457939 | Second-line chemotherapy in head and neck cancer: what should we expect? |
| Q35070422 | Second-line chemotherapy of epithelial ovarian cancer |
| Q38020244 | Second-line systemic therapy for the treatment of metastatic renal cell cancer. |
| Q36842786 | Second-line therapy for esophageal cancer |
| Q37866795 | Second-line therapy for small-cell lung cancer |
| Q37945643 | Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? |
| Q36448699 | Second-line treatment of postmenopausal women with advanced breast carcinoma |
| Q47789861 | Second-line treatments of small-cell lung cancers |
| Q37752365 | Seizures in low- and high-grade gliomas: current management and future outlook |
| Q36500558 | Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer |
| Q37782096 | Selecting multimodal therapy for rhabdomyosarcoma |
| Q38020245 | Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when |
| Q38255032 | Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives |
| Q36605347 | Sellar lesions and visual loss: key concepts in neuro-ophthalmology |
| Q38132245 | Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas |
| Q36636663 | Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer |
| Q35918475 | Sentinel lymph node biopsy for breast cancer: from investigational procedure to standard practice |
| Q38286125 | Sentinel lymph node biopsy for cutaneous head and neck malignancies |
| Q35576177 | Sentinel lymph node biopsy for melanoma of the head and neck |
| Q36668256 | Sequelae following axillary lymph node dissection for breast cancer |
| Q38162290 | Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. |
| Q38068584 | Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. |
| Q38978839 | Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management |
| Q82932516 | Serum tumor markers and their utilization in the management of germ-cell tumors in adult males |
| Q35918479 | Serum tumor markers in patients with breast cancer. |
| Q98393528 | Sex-based differences in outcomes of patients with HPV-positive versus HPV-negative oropharyngeal carcinoma: a population-based study |
| Q37774351 | Sexual morbidity following radical hysterectomy for cervical cancer |
| Q39167766 | Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials |
| Q37845827 | Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? |
| Q37561979 | Should anti-mesothelin therapies be explored in lung cancer? |
| Q92521310 | Should chemotherapy still be used to treat all muscle invasive bladder cancer in the "era of immunotherapy"? |
| Q46698757 | Should docetaxel be administered earlier in prostate cancer therapy? |
| Q84002224 | Should photodynamic diagnosis be standard practice for bladder cancer? |
| Q37774352 | Should prostate-specific antigen screening be offered to asymptomatic men? |
| Q100455935 | Should triple-positive breast cancer be recognized as a distinct subtype? |
| Q37774350 | Should we follow-up serum testosterone in patients with advanced prostate cancer? |
| Q81547224 | Should we modify the current FIGO staging system for early-stage cervical cancer? |
| Q35987785 | Signaling multiplex of the epidermal growth factor receptor |
| Q36974710 | Significance and management of micrometastases in patients with breast cancer |
| Q36381308 | Significance of gene expression analysis of renal cell carcinoma. |
| Q36974719 | Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application? |
| Q38447570 | Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy |
| Q37782093 | Simultaneous targeting of estrogen receptor and HER2 in breast cancer |
| Q38088000 | Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. |
| Q36613961 | Sipuleucel-T (APC8015) for prostate cancer |
| Q37821894 | Sipuleucel-T for prostate cancer: the immunotherapy era has commenced |
| Q43836757 | Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas? |
| Q38156189 | Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments |
| Q36689123 | Small-cell carcinoma of the urinary bladder: diagnosis and management |
| Q37845825 | Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk |
| Q37483944 | Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors |
| Q37894667 | Sorafenib for the management of advanced renal cell carcinoma |
| Q55053748 | Sorafenib in the treatment of thyroid cancer. |
| Q37614576 | Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer |
| Q45982820 | Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. |
| Q36817095 | Sorafenib: delivering a targeted drug to the right targets |
| Q90692179 | Sorafenib: key lessons from over 10 years of experience |
| Q37873467 | Specific challenges in the management of subungual melanoma. |
| Q37449030 | Specifically targeted gene therapy for small-cell lung cancer. |
| Q37030812 | Spectrum of pediatric gliomas: implications for the development of future therapies |
| Q37788239 | Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas |
| Q89018896 | Spotlight on atezolizumab and its potential as an oncology agent |
| Q58595788 | Squamous cell carcinoma of the vulva: a review of present management and future considerations |
| Q34734102 | Staging in prostate cancer |
| Q92045729 | Starvation in cancer cells: circulating arginine is good for cancer but bad for patients |
| Q37873463 | State of the art of diagnostic technology for early-stage melanoma |
| Q37614564 | State-of-the-art lung cancer radiation therapy |
| Q37025964 | State-of-the-art mandible reconstruction using revascularized free-tissue transfer |
| Q36950495 | State-of-the-art surgical management of renal cell carcinoma |
| Q36950503 | State-of-the-art surgical management of testicular tumors |
| Q37256833 | Stathmin 1: a novel therapeutic target for anticancer activity |
| Q39828211 | Statin use is associated with improved prostate cancer survival: is it time for a clinical trial? |
| Q30235361 | Statistical approaches for evaluating body composition markers in clinical cancer research |
| Q36752029 | Stem cell transplantation in Hodgkin lymphoma. |
| Q37799828 | Stem cells in gastrointestinal cancers: a matter of choice in cell fate determination |
| Q36381291 | Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer |
| Q37038910 | Stereotactic body radiation therapy for early-stage non-small-cell lung cancer |
| Q38068588 | Stereotactic body radiation therapy for metastasis to the adrenal glands |
| Q37338255 | Stereotactic body radiation therapy for nonpulmonary primary tumors |
| Q37483976 | Stereotactic body radiation therapy for oligometastases |
| Q38245676 | Stereotactic body radiation therapy in pancreatic cancer: the new frontier |
| Q38808288 | Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? |
| Q38783194 | Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions |
| Q38374340 | Stereotactic body radiotherapy in operable patients with stage I NSCLC: where is the evidence? |
| Q90995856 | Stereotactic body radiotherapy in patients with multiple lung tumors: a focus on lung dosimetric constraints |
| Q37960918 | Stereotactic body radiotherapy is an effective treatment in reirradiating spinal metastases: current status and practical considerations for safe practice |
| Q38836152 | Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach. |
| Q38230692 | Stereotactic radiosurgery for multiple brain metastases |
| Q37952241 | Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. |
| Q38933888 | Strategic overview on the best treatment option for intrahepaitc hepatocellular carcinoma recurrence |
| Q34409666 | Strategies to improve outcomes in esophageal adenocarcinoma. |
| Q83645730 | Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling |
| Q30391641 | Structural and functional analysis of human prostatic acid phosphatase |
| Q74450428 | Study shows 2-year survival advantage for docetaxel |
| Q85718321 | Sublobar/wedge resection or stereotactic body radiation therapy for stage I marginally operable non-small-cell lung cancer |
| Q81055564 | Successful targeted therapies for hepatocellular carcinoma: are we really getting there? |
| Q51171168 | Summary of the 15th annual Atlantic Canada Oncology Group Symposium. |
| Q37301234 | Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma |
| Q37960905 | Sunitinib for advanced pancreatic neuroendocrine tumors. |
| Q37705402 | Sunitinib for the management of advanced renal cell carcinoma |
| Q39038214 | Sunitinib in kidney cancer: 10 years of experience and development. |
| Q36689131 | Superficial bladder cancer: part 1. Update on etiology, classification and natural history |
| Q36788508 | Superficial bladder cancer: part 2. Management |
| Q85021551 | Superficial esophageal cancer: endoscopic resection or radical surgery? |
| Q37086010 | Supportive care for women with gynecologic cancers |
| Q47417335 | Surface-enhanced Raman spectroscopy + support vector machine: a new noninvasive method for prostate cancer screening? |
| Q80273838 | Surgery |
| Q37338251 | Surgery for oligometastatic disease in non-small-cell lung cancer |
| Q38048821 | Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum |
| Q36613982 | Surgery of lymph nodes in papillary thyroid cancer |
| Q88567949 | Surgical approaches for the treatment of perihilar cholangiocarcinoma |
| Q84971450 | Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure |
| Q35611853 | Surgical management of bladder cancer in 2003. |
| Q37656222 | Surgical management of chemotherapy-resistant gestational trophoblastic neoplasia |
| Q38763639 | Surgical management of extra-regional lymph node metastasis in colorectal cancer. |
| Q37960913 | Surgical management of large renal tumors |
| Q91876727 | Surgical management of pancreatic neuroendocrine tumors: an introduction |
| Q31139817 | Surgical management of pediatric brain tumors |
| Q88116251 | Surgical management of spinal metastases |
| Q81346012 | Surgical management of thyroid cancer |
| Q104563792 | Surgical oncology in the age of multimodality therapy for cancers of the upper and lower gastrointestinal tract |
| Q36381285 | Surgical options and outcomes in bone sarcoma |
| Q81346026 | Surgical therapy of genitourinary cancers |
| Q38841987 | Surrogate endpoints for overall survival in lung cancer trials: a review |
| Q37909369 | Symptom management in gynecologic malignancies |
| Q38139997 | Synoptic pathology reporting for thyroid cancer: a review and institutional experience |
| Q36264073 | Synthetic high-density lipoprotein-like nanoparticles for cancer therapy |
| Q36788454 | Synthetic retinoid fenretinide in breast cancer chemoprevention |
| Q36879176 | Systemic and global toxicities of head and neck treatment |
| Q36500537 | Systemic chemotherapy options for metastatic bladder cancer |
| Q37118940 | Systemic therapies for recurrent and/or metastatic salivary gland cancers |
| Q35089138 | Systemic therapy for advanced pancreatic cancer |
| Q37546032 | Systemic therapy for recurrent endometrial cancer: a review of North American trials |
| Q37894680 | Systemic therapy for sarcomatoid renal cell carcinoma |
| Q37656225 | Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. |
| Q38194591 | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
| Q91827125 | Systemic treatment of advanced hepatocellular cancer: new hope on the horizon |
| Q38933836 | Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? |
| Q38495486 | Systemic treatment of vulvar cancer |
| Q36407458 | Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. |
| Q84071368 | T-cell lymphoma forum |
| Q51775280 | T-cell prolymphocytic leukemia. |
| Q36297606 | T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy. |
| Q37300023 | TACE versus TAE as therapy for hepatocellular carcinoma |
| Q38618169 | TAS-102 for the treatment of metastatic colorectal cancer. |
| Q104493976 | TIM-3 pathway dysregulation and targeting in cancer |
| Q34734027 | TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies |
| Q38680652 | Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment |
| Q39209020 | Tackling non-muscle invasive bladder cancer in the clinic |
| Q95926550 | Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm |
| Q73334866 | Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance? |
| Q80307084 | Targeted TGF-beta chemotherapies: friend or foe in treating human malignancies? |
| Q38980703 | Targeted adjuvant therapy in breast cancer |
| Q38760610 | Targeted agents and combinations in ovarian cancer: where are we now? |
| Q35782949 | Targeted alpha-therapy for control of micrometastatic prostate cancer |
| Q57796985 | Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives |
| Q35641242 | Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins |
| Q73561193 | Targeted monoclonal antibody-based treatment of hematological malignancies |
| Q53111022 | Targeted silencing of Survivin in cancer cells by siRNA loaded chitosan magnetic nanoparticles. |
| Q36817135 | Targeted therapies for soft-tissue sarcomas |
| Q36689148 | Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel |
| Q47351169 | Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors |
| Q35641209 | Targeted therapies in oncology: in the crosshairs or at the crossroads? |
| Q37952233 | Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. |
| Q90306727 | Targeted therapy for metastatic colorectal cancer |
| Q37709922 | Targeted therapy for non-small-cell lung cancer: past, present and future |
| Q37038914 | Targeted therapy in chronic myeloid leukemia |
| Q74450426 | Targeted therapy in oncology: the agony and ecstasy of personalized medicine |
| Q38333251 | Targeted therapy of acute myeloid leukemia |
| Q84666515 | Targeted therapy: overcoming drug resistance with clinical cancer genome |
| Q54475304 | Targeted treatment for melanoma. |
| Q38633308 | Targeting HER 2 and angiogenesis in gastric cancer |
| Q38081245 | Targeting RANKL in breast cancer: bone metastasis and beyond |
| Q53736404 | Targeting SWI/SNF mutant cancers with tyrosine kinase inhibitor therapy. |
| Q45364512 | Targeting activated Rho proteins: a new approach for treatment of HPV and other virus-related cancers? |
| Q39235260 | Targeting adenosine in cancer immunotherapy: a review of recent progress. |
| Q37449058 | Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab |
| Q91205902 | Targeting angiogenesis in metastatic renal cell carcinoma |
| Q36500552 | Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma |
| Q52651080 | Targeting cytokine networks in KRAS-driven tumorigenesis. |
| Q36613969 | Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer |
| Q37030810 | Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma |
| Q35160217 | Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer |
| Q36668233 | Targeting events in melanoma carcinogenesis for the prevention of melanoma |
| Q50912525 | Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. |
| Q30388849 | Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale? |
| Q37317000 | Targeting important pathways in head and neck cancer: from the bench to the clinic |
| Q35843730 | Targeting mTOR-mediated survival signals in anticancer therapeutic strategies |
| Q38892486 | Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck |
| Q28081364 | Targeting protein kinase C subtypes in pancreatic cancer |
| Q35987779 | Targeting protein kinases in cancer therapy: a success? |
| Q39007517 | Targeting reactive oxygen species in development and progression of pancreatic cancer |
| Q38002473 | Targeting the Met pathway in lung cancer |
| Q37331862 | Targeting the Met signaling pathway in renal cancer. |
| Q36842782 | Targeting the PI3K-Akt pathway in kidney cancer |
| Q42240464 | Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy? |
| Q37256842 | Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers |
| Q38263575 | Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. |
| Q95386914 | Targeting the leptin receptor: a potential new mode of treatment for breast cancer |
| Q36334912 | Targeting the stromal fibroblasts: a novel approach to melanoma therapy |
| Q92426992 | Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma |
| Q35728789 | Targeting the tumor vasculature: a strategy to improve radiation therapy |
| Q36788503 | Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma |
| Q38815319 | Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma |
| Q82678221 | Targeting thrombosis in exocrine pancreas cancer: a continued need for improved therapies |
| Q36788463 | Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor |
| Q37086007 | Taxanes in the management of gynecologic malignancies |
| Q39380221 | Telemedical technologies in urological cancer care: past, present and future applications |
| Q34734539 | Telomerase as a diagnostic and therapeutic target for cancer |
| Q37866781 | Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. |
| Q33372340 | Temozolomide: a milestone in neuro-oncology and beyond? |
| Q34734267 | Temozolomide: a novel oral alkylating agent |
| Q86904822 | Temsirolimus for advanced renal cell carcinoma |
| Q38101614 | Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives |
| Q37752347 | Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges. |
| Q36284481 | Thalidomide and dexamethasone: therapy for multiple myeloma. |
| Q34734291 | Thalidomide in the treatment of multiple myeloma |
| Q36066131 | Thalidomide: present and future in multiple myeloma |
| Q48609354 | The 'digital eye' at the threshold of cancer diagnosis |
| Q40152233 | The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer |
| Q47736746 | The Breast Health Global Initiative: clinical practice guidelines for management of breast cancer in low- and middle-income countries |
| Q36817100 | The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer |
| Q94958971 | The COVID-19 outbreak: a snapshot from down under |
| Q46682601 | The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer |
| Q39621018 | The First Children's Cancer Hospital, Egypt International Scientific Conference |
| Q39752575 | The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer |
| Q97542169 | The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma |
| Q37357294 | The NSABP Study of Tamoxifen and Raloxifene (STAR) trial |
| Q81501621 | The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval |
| Q81722078 | The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval |
| Q81088593 | The ODAC Chronicles: Part 6a. ODAC's structure and function |
| Q81343540 | The ODAC Chronicles: part 6b. ODAC's structure and function |
| Q48464903 | The ODAC Chronicles: part 7. Tale of two goals |
| Q81162209 | The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art? |
| Q80343812 | The ODAC chronicles: Part 5. Prostate cancer endpoints |
| Q80863578 | The ODAC chronicles: part 1. My first ODAC experience |
| Q39317811 | The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. |
| Q84225034 | The USA's healthcare debacle: the role of the US FDA |
| Q82470293 | The USA’s healthcare reform: the cost of prescription medicines |
| Q34632285 | The Wnt signaling pathway: implications for therapy in osteosarcoma |
| Q114869578 | The Wnt/β-catenin pathway in breast cancer therapy: a pre-clinical perspective of its targeting for clinical translation |
| Q38482991 | The acetyl-CoA carboxylase enzyme: a target for cancer therapy? |
| Q89754440 | The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy |
| Q40872029 | The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia |
| Q54502994 | The beautiful history of pertuzumab. |
| Q87489588 | The benefit of chemotherapy in elderly patients with small cell lung cancer |
| Q35160195 | The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. |
| Q83461340 | The cancer stem cell paradigm in Ewing's sarcoma: what can we learn about these rare cells from a rare tumor? |
| Q79392835 | The cancer stem cell: a new therapeutic paradigm? |
| Q37982451 | The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: the Italian pediatric oncology view. |
| Q38132244 | The challenges of individualized care for older patients with localized breast cancer |
| Q58080247 | The changing face of treatment for metastatic colorectal cancer |
| Q97542296 | The changing landscape of stage III lung cancer: a literature review |
| Q38132239 | The classification of invasive carcinoma of the breast |
| Q37909375 | The clinical and therapeutic implications of cancer stem cell biology |
| Q90780438 | The clinical applications of The Cancer Genome Atlas project for bladder cancer |
| Q38783340 | The clinical management of inoperable endometrial carcinoma |
| Q38136287 | The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma |
| Q38570399 | The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes |
| Q46221202 | The coexistence of clear cell renal cell carcinoma and gastrointestinal stromal tumor with portal vein metastasis, and its favorable response to sunitinib |
| Q89962321 | The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review |
| Q48204740 | The cost and value of glioblastoma therapy |
| Q96342636 | The current clinical approach to newly diagnosed uterine cancer |
| Q38168923 | The current position and the future perspectives of cervical cancer screening |
| Q94460165 | The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments |
| Q97417478 | The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia |
| Q38830852 | The current status of immunotherapy in peritoneal carcinomatosis |
| Q47278103 | The development of PARP as a successful target for cancer therapy |
| Q57178070 | The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic |
| Q33435178 | The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. |
| Q52633087 | The diagnosis and management of extramammary Paget's disease. |
| Q38552886 | The diagnostic and prognostic role of liquid-based cytology: are we ready to monitor therapy and resistance? |
| Q56976222 | The diagnostic challenge of salivary gland malignancies |
| Q98305824 | The diagnostic challenges of patients with carcinoma of unknown primary |
| Q37960911 | The dilemma of cystectomy in old-old and oldest-old patients |
| Q36448679 | The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer |
| Q98724073 | The effects of exercise on cancer-related fatigue in breast cancer patients during primary treatment: a meta-analysis and systematic review |
| Q56975716 | The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer |
| Q89163202 | The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care |
| Q98215368 | The emerging role of PARP inhibitors in prostate cancer |
| Q96582365 | The emerging role of antibody-drug conjugates in urothelial carcinoma |
| Q36352082 | The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications |
| Q89237290 | The evolution and rise of stereotactic body radiotherapy (SBRT) for spinal metastases |
| Q48098689 | The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. |
| Q83404605 | The evolution of antiandrogens: MDV3100 comes of age |
| Q33274710 | The evolution of systemic therapy in sarcoma. |
| Q38083816 | The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer |
| Q90603622 | The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma |
| Q38823537 | The evolving role of radiation therapy in pediatric Hodgkin's disease |
| Q38625125 | The evolving role of radiotherapy in treatment of oligometastatic NSCLC. |
| Q90009826 | The evolving role of receptors as predictive biomarkers for metastatic breast cancer |
| Q100306501 | The evolving role of time-limited targeted therapy in chronic lymphocytic leukemia |
| Q37960912 | The expanding role of imaging in the management of renal cell carcinoma |
| Q86547720 | The first antibody therapy for cancer: a personal experience |
| Q45730724 | The founding of the European Cooperative Study Group on Pediatric Rare Tumors--EXPeRT. |
| Q36066186 | The future of adjuvant chemotherapy for resected non-small cell lung cancer |
| Q38683944 | The future of oncology therapeutics. |
| Q92141167 | The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis |
| Q37866790 | The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer |
| Q104739008 | The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma |
| Q35987743 | The importance of an extended lymphadenectomy in the management of high-grade invasive bladder cancer |
| Q49041778 | The importance of fertility preservation in cancer patients |
| Q38534294 | The importance of the tumor microenvironment in the therapeutic management of cancer |
| Q74450382 | The importance of tumor banking: bridging no-mans-land in cancer research |
| Q37934960 | The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again |
| Q38284474 | The incidence of second brain tumors related to cranial irradiation |
| Q38149984 | The influence of pH and hypoxia on tumor metastasis |
| Q43756770 | The intriguing patterns of tumor response to trabectedin |
| Q91008990 | The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib |
| Q47604110 | The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases |
| Q38411314 | The management of head and neck tumors with high technology radiation therapy |
| Q38243969 | The miRNA network: micro-regulator of cell signaling in cancer |
| Q93359693 | The molecular characterization and therapeutic strategies of papillary renal cell carcinoma |
| Q38199182 | The multidisciplinary management of giant cell tumor of bone |
| Q87826429 | The need for active surveillance for low risk prostate cancer |
| Q104109686 | The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma |
| Q85187615 | The need to revisit adjuvant and neoadjuvant radiotherapy in bladder cancer |
| Q83461338 | The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? |
| Q34121078 | The origins of urothelial carcinoma |
| Q91110164 | The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors |
| Q38087999 | The place of pemetrexed in the management of non-small-cell lung cancer patients |
| Q89462441 | The potential of BRAF-targeted therapy combined with immunotherapy in melanoma |
| Q98612561 | The potential of PSMA-targeted alpha therapy in the management of prostate cancer |
| Q100378697 | The potential of cystatin C as a predictive biomarker in breast cancer |
| Q45365447 | The potential of virus-based gene therapies for treatment of metastatic kidney cancer |
| Q91506460 | The prognostic role of circulating tumor cells in colorectal cancer |
| Q38874709 | The prognostic role of circulating tumor cells in lung cancer. |
| Q37988568 | The rise of transoral robotic surgery in the head and neck: emerging applications |
| Q49185620 | The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next? |
| Q102386891 | The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma |
| Q38162925 | The role of Gliadel wafers in the treatment of high-grade gliomas |
| Q37788240 | The role of PET in Hodgkin’s lymphoma and its impact on radiation oncology |
| Q38002465 | The role of abiraterone in the management of metastatic castration-resistant prostate cancer |
| Q39266433 | The role of adhesions between homologous cancer cells in tumor progression and targeted therapy. |
| Q36811788 | The role of adjuvant therapy in uterine leiomyosarcoma |
| Q38981789 | The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer |
| Q38910225 | The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer |
| Q85251376 | The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer |
| Q36773130 | The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer |
| Q38126946 | The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy |
| Q93271428 | The role of circulating free DNA in the management of NSCLC |
| Q38575004 | The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target |
| Q92678941 | The role of combination chemo-immunotherapy in advanced non-small cell lung cancer |
| Q50518337 | The role of external beam radiation therapy in well-differentiated thyroid cancer. |
| Q36381282 | The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. |
| Q38653106 | The role of hyperthermia as a treatment for non-muscle invasive bladder cancer |
| Q38020246 | The role of laparoscopy and robotic surgery in the management of small renal masses |
| Q39096266 | The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges |
| Q92496206 | The role of metastasectomy in advanced renal cell carcinoma |
| Q38162921 | The role of metastasectomy in renal cell carcinoma |
| Q88032367 | The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer |
| Q38068581 | The role of narrow-band imaging in the management of non-muscle-invasive bladder cancer. |
| Q38123208 | The role of necroptosis, an alternative form of cell death, in cancer therapy |
| Q52596807 | The role of neoadjuvant chemotherapy in ovarian cancer. |
| Q38653169 | The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review |
| Q92817891 | The role of nutrition in pediatric oncology |
| Q37242670 | The role of platelet activation in tumor metastasis. |
| Q38375425 | The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia |
| Q57105298 | The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection |
| Q87405738 | The role of radioembolization in colorectal cancer treatment |
| Q35272050 | The role of sexual behavior in head and neck cancer: implications for prevention and therapy |
| Q38234464 | The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors |
| Q30249789 | The role of surgery in recurrent endometrial cancer |
| Q38048820 | The role of surgery in the multidisciplinary management of patients with localized gastrointestinal stromal tumors |
| Q38168919 | The role of systemic and targeted therapies in brain metastases |
| Q101049310 | The role of the microbiome in drug resistance in gastrointestinal cancers |
| Q37894669 | The role of tissue microarray in the era of target-based agents. |
| Q90803287 | The role of tivozanib in advanced renal cell carcinoma therapy |
| Q47729622 | The role of tumor angiogenesis as a therapeutic target in colorectal cancer |
| Q38594492 | The roles of CD147 in the progression of gliomas |
| Q38843097 | The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy |
| Q38810865 | The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer |
| Q38843111 | The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma |
| Q38841082 | The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer |
| Q38701535 | The safety and efficacy of gemcitabine for the treatment of bladder cancer |
| Q38825250 | The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. |
| Q38917461 | The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer |
| Q38817846 | The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer |
| Q37085219 | The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer |
| Q38709347 | The safety and efficacy of palbociclib in the treatment of metastatic breast cancer |
| Q38921712 | The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer |
| Q38825283 | The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer. |
| Q39337947 | The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer |
| Q38942944 | The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma |
| Q38892507 | The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes |
| Q38820516 | The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma |
| Q38797843 | The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. |
| Q38960074 | The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. |
| Q38210665 | The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme |
| Q38664762 | The state of regional therapy in the management of metastatic colorectal cancer to the liver |
| Q89367141 | The therapeutic potential of natural killer cells to target medulloblastoma |
| Q91828221 | The use of alternative therapies in conjunction with opioids for cancer pain |
| Q90295980 | The use of cytoreductive nephrectomy in patients with renal cell carcinoma |
| Q92352716 | The use of in vivo reflectance confocal microscopy for the diagnosis of melanoma |
| Q90210110 | The use of intraperitoneal chemotherapy for gastric malignancies |
| Q48634468 | The use of sunitinib in renal cell carcinoma: where are we now? |
| Q38683638 | The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations? |
| Q37004688 | The utility of ultrasound in patients with melanoma |
| Q100521108 | The value of tumor mutational burden to select patients for immunotherapy |
| Q83153095 | The wind of change in the therapy of lung cancer |
| Q34733957 | Therapeutic advances in the management of metastatic colorectal cancer |
| Q90768447 | Therapeutic approaches for T790M mutation positive non-small-cell lung cancer |
| Q93006664 | Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer |
| Q52667403 | Therapeutic approaches for refractory germ cell cancer. |
| Q36499222 | Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology |
| Q44210690 | Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma |
| Q36235581 | Therapeutic endoscopy and endoscopic ultrasound for gastrointestinal malignancies |
| Q38964037 | Therapeutic management of bone metastasis in prostate cancer: an update |
| Q34734208 | Therapeutic management of primary CNS lymphoma in immunocompetent patients |
| Q34734137 | Therapeutic options and treatment of muscle invasive bladder cancer |
| Q37934968 | Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises |
| Q37931893 | Therapeutic potential of PARP inhibitors for metastatic breast cancer |
| Q37577912 | Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities |
| Q37982442 | Therapeutic potential of irreversible electroporation in sarcoma |
| Q90247595 | Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer |
| Q50077471 | Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy |
| Q88921883 | Therapeutic strategies for upper tract urothelial carcinoma |
| Q36613990 | Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma |
| Q34588402 | Therapies in development for castrate-resistant prostate cancer |
| Q37809862 | Therapy and prophylaxis of brain metastases |
| Q100571440 | Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach |
| Q37873464 | Therapy for metastatic melanoma: an overview and update |
| Q35918439 | Therapy for recurrent malignant glioma in adults |
| Q37945640 | Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients |
| Q36066166 | Therapy of testicular cancer: a surgeon's view |
| Q34734214 | Therapy options in cutaneous T-cell lymphoma |
| Q51163819 | Third annual forum on T-cell lymphoma. |
| Q92871990 | Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC) |
| Q83521499 | Thromboprophylaxis in multiple myeloma: is the evidence there? |
| Q28219961 | Thrombosis in multiple myeloma |
| Q38114948 | Thymoma and radiation therapy: a systematic review of medical treatment |
| Q39034554 | Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials |
| Q37821896 | Timing for starting second-line therapy in recurrent ovarian cancer |
| Q36407429 | Tipifarnib: farnesyl transferase inhibition at a crossroads |
| Q90963150 | Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia |
| Q36573836 | Tissue detection of biomolecular predictors in breast cancer |
| Q38513062 | Tivantinib (ARQ197) in hepatocellular carcinoma |
| Q38114944 | Tivozanib for the treatment of metastatic renal cancer |
| Q37038875 | To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision? |
| Q103015980 | To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today? |
| Q37159504 | Topoisomerase I inhibitors for the treatment of brain tumors |
| Q36842752 | Topotecan for the treatment of small-cell lung cancer |
| Q36974695 | Total mesorectal excision and management of rectal cancer. |
| Q88177931 | Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer |
| Q37542942 | Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts |
| Q38196963 | Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes |
| Q35671104 | Towards global consensus in the treatment of gastrointestinal stromal tumor |
| Q34978252 | Towards personalized therapy for patients with glioblastoma |
| Q37508022 | Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma |
| Q37338263 | Toxicity of targeted therapies in elderly patients |
| Q52744336 | Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. |
| Q91488720 | Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study |
| Q37765581 | Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer |
| Q33384836 | Trabectedin for the management of soft-tissue sarcoma |
| Q57570780 | Trabectedin’s contribution to the treatment of sarcomas |
| Q38536713 | Trametinib in metastatic melanoma |
| Q74450676 | TransMolecular receives FDA approval for 131-I-TM-601 IND application |
| Q38559105 | Transanal total mesorectal excision for rectal cancer: The journey towards a new technique and its current status |
| Q38213650 | Transarterial chemoembolization and sorafenib in hepatocellular carcinoma |
| Q48663024 | Transcription factors as master regulator for cancer stemness: remove milk from fox? |
| Q33538827 | Transoral laser microsurgery for early laryngeal cancer |
| Q36605378 | Transsphenoidal microsurgery: past, present and future |
| Q37687375 | Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls |
| Q38052616 | Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients |
| Q103016031 | Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy |
| Q44552912 | Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets |
| Q52686458 | Treating breakthrough pain in oncology. |
| Q38030592 | Treating patients with metastatic renal carcinoma: an escape from Phase III. |
| Q91295776 | Treating patients with renal cell carcinoma and bone metastases |
| Q80488901 | Treating the genetic make-up of breast cancer: a new fashion? |
| Q94542399 | Treating the genetic make-up of breast cancer: a new fashion? |
| Q100441825 | Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse |
| Q101236431 | Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making? |
| Q35070441 | Treatment for cancer-related fatigue: an update |
| Q94675967 | Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy |
| Q37411171 | Treatment of Barrett's esophagus with high-grade dysplasia |
| Q36407453 | Treatment of Burkitt lymphoma in adults |
| Q34734242 | Treatment of acute leukemia in children: recent advances and future challenges |
| Q36752023 | Treatment of acute myeloid leukemia in older patients |
| Q38139992 | Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions |
| Q89102834 | Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists? |
| Q34722383 | Treatment of bicalutamide-induced breast events |
| Q35918442 | Treatment of brain metastases in uncommon tumors. |
| Q36284532 | Treatment of childhood acute myeloid leukemia |
| Q38665322 | Treatment of elderly patients with metastatic renal cell carcinoma |
| Q37965641 | Treatment of elderly patients with stage IV non-small-cell lung cancer |
| Q38962913 | Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. |
| Q36407449 | Treatment of gastric mucosa-associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond |
| Q36185627 | Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling |
| Q38096477 | Treatment of hepatocellular carcinoma: present and future |
| Q36605366 | Treatment of infertility in women with pituitary tumors |
| Q33207913 | Treatment of laryngeal cancer: the permanent challenge |
| Q37628708 | Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides |
| Q36185624 | Treatment of mantle cell lymphoma: targeting the microenvironment |
| Q37821906 | Treatment of men with rising prostate-specific antigen levels following radical prostatectomy |
| Q36950492 | Treatment of muscle-invasive bladder cancer. |
| Q35987756 | Treatment of muscle-invasive bladder cancer: progress and new challenges |
| Q36817114 | Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail |
| Q33239855 | Treatment of primary intraocular melanoma |
| Q98476377 | Treatment of recurrent glioblastoma: state-of-the-art and future perspectives |
| Q35987766 | Treatment of recurrent or metastatic renal cell carcinoma |
| Q34734034 | Treatment of refractory and relapsed acute myelogenous leukemia |
| Q37642795 | Treatment of relapsed Wilms tumors: lessons learned. |
| Q37357311 | Treatment of resectable gastric cancer: current standards of care |
| Q36573843 | Treatment of sentinel node-positive breast cancer |
| Q36691799 | Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age. |
| Q35117759 | Treatment of tumor-induced hypercalcemia: a solved problem? |
| Q90103880 | Treatment options after first-line immunotherapy in metastatic NSCLC |
| Q38062020 | Treatment options for advanced pancreatic cancer: a review |
| Q36284501 | Treatment options for brain metastases from melanoma |
| Q35728719 | Treatment options for children with nonrhabdomyosarcoma soft tissue sarcoma |
| Q35728668 | Treatment options for early breast cancer in elderly women |
| Q36500561 | Treatment options for older woman with early breast cancer |
| Q37483971 | Treatment options for recurrent glioblastoma: pitfalls and future trends |
| Q37614582 | Treatment options for stage I non-small-cell lung carcinoma patients not suitable for lobectomy |
| Q80955269 | Treatment outcomes for patients with synovial sarcoma of the head and neck |
| Q50521086 | Trends in melanoma incidence among children: possible influence of sun-protection programs. |
| Q38824019 | Triage of high-risk HPV positive women in cervical cancer screening. |
| Q45205793 | Trials and tribulations of cytotoxic and targeted breast cancer therapy: a clinical perspective on the next phase of progress. Interview by Sophia Maprayil and Alexandra Hemsley |
| Q37118960 | Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory? |
| Q57457266 | Trimodal therapy for muscle-invasive bladder cancer |
| Q37812608 | Trimodality treatment for bladder cancer: does modern radiotherapy improve the end results? |
| Q102073380 | Triple-negative breast cancer: promising prognostic biomarkers currently in development |
| Q37687380 | Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features |
| Q34734015 | Troxacitabine-based therapy of refractory leukemia |
| Q37894675 | Tumor enucleation: a safe treatment alternative for renal cell carcinoma |
| Q90065493 | Tumor heterogeneity: does it matter? |
| Q37598949 | Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses |
| Q42109084 | Tumor microenvironment regulates epithelial-mesenchymal transitions in metastasis |
| Q38154959 | Tumor-associated edema in brain cancer patients: pathogenesis and management |
| Q34272962 | Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia |
| Q47681377 | Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer |
| Q83159693 | USA's healthcare reform: challenges and opportunities |
| Q82781681 | USA's healthcare reform: why it will not work |
| Q37821902 | Ultrasound-based combination therapy: potential in urologic cancer |
| Q53646166 | Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal? |
| Q42909161 | Unconventional therapies in ocular adnexal lymphomas |
| Q58099935 | Uncovering the links between diet and the incidence of bowel cancer |
| Q38808249 | Understanding dendritic cell immunotherapy in ovarian cancer |
| Q87567292 | Understanding p53: new insights into tumor suppression |
| Q37765586 | Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy |
| Q38859683 | Undetected lymph node metastases in presumed early stage NSCLC SABR patients |
| Q83645718 | Unexpected AZURE results lead to rethink for Zometa(®) |
| Q48614301 | Unmet needs in the treatment of glioblastoma |
| Q42156798 | Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering |
| Q37705418 | Unraveling the interactions between environmental factors and genetic polymorphisms in non-Hodgkin lymphoma risk |
| Q37765590 | Unravelling the complexity of cancer-immune system interplay |
| Q37705417 | Unresolved issues in diffuse large B-cell lymphomas |
| Q37821897 | Unresolved issues in the management of endometrial cancer |
| Q37086017 | Update in systemic therapy of prostate cancer: improvement in quality and duration of life |
| Q51741328 | Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer. |
| Q36879135 | Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival |
| Q37577923 | Update on genetic predisposition to breast cancer |
| Q38879904 | Update on medical treatment of small intestinal neuroendocrine tumors |
| Q37960908 | Update on melanoma and non-melanoma skin cancer. Annual Skin Cancer Conference 2011, Hamilton Island, Australia, 5–6 August 2011. |
| Q38101606 | Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. |
| Q37642798 | Update on novel agents in renal cell carcinoma |
| Q38787278 | Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. |
| Q90425295 | Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019 |
| Q34734324 | Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia |
| Q80603453 | Update on staging controversies for locally advanced renal cell carcinoma |
| Q36066169 | Update on surgical treatment for endometrial cancer |
| Q38237463 | Update on systemic therapy of advanced non-small-cell lung cancer |
| Q37656218 | Update on the sentinel lymph node procedure in vulvar cancer |
| Q35576174 | Update on the therapeutic approaches to brain tumors |
| Q35576166 | Update on the treatment of neuroendocrine tumors |
| Q36691820 | Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance |
| Q37183479 | Upper gastrointestinal tumors: current status and future perspectives |
| Q36689127 | Urachal carcinoma: surgical and chemotherapeutic options |
| Q38020241 | Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential |
| Q37965638 | Urothelial cancers: using biology to improve outcomes |
| Q38068582 | Urothelial carcinoma in both adnexa following perforation during transurethral resection of a non-muscle-invasive bladder tumor: a case report and literature review |
| Q36752053 | Urothelial carcinoma in the prostatic urethra and prostate: current controversies |
| Q95279021 | Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors |
| Q36614009 | Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme |
| Q34734220 | Use of adjuvant therapy in cutaneous melanoma |
| Q38503419 | Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations |
| Q37794991 | Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. |
| Q36573831 | Use of autoantibodies in breast cancer screening and diagnosis. |
| Q36532076 | Use of bortezomib in B-cell non-Hodgkin's lymphoma |
| Q36235537 | Use of goserelin in the treatment of breast cancer |
| Q36499230 | Use of high-dose chemotherapy in front-line therapy of childhood malignant glioma |
| Q37614587 | Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer |
| Q37965631 | Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts |
| Q36573813 | Use of trastuzumab for the treatment of early stage breast cancer |
| Q37025939 | Use of ultrasound to early identify, diagnose and localize metastases in melanoma patients |
| Q37038901 | VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment |
| Q80145429 | VIth meeting on cancer-induced bone disease |
| Q36066161 | Vaccination strategies for the prevention of cervical cancer |
| Q36573868 | Vaccination: role in metastatic melanoma. |
| Q36950477 | Vaccine immunotherapy in breast cancer treatment: promising, but still early. |
| Q38633884 | Valrubicin in refractory non-muscle invasive bladder cancer |
| Q57339637 | Value and difficulties of a common European strategy for recurrent Wilms’ tumor |
| Q92612381 | Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: a meta-analysis |
| Q40506794 | Vasectomy: potential links to an increased risk of aggressive prostate cancer? |
| Q38101603 | Vemurafenib in melanoma |
| Q35728779 | Venous thromboembolism and malignancy |
| Q78380601 | Vical updates Allovectin-7 melanoma program |
| Q37821892 | Vinflunine in the treatment of advanced bladder cancer |
| Q78380616 | Vion initiates phase I trial of Tapet with immune system modulation |
| Q83883675 | Virtual reality surgical simulation in training |
| Q81900246 | Viruses in head and neck cancers: prevention and therapy |
| Q82670950 | Vitamin D (and its analogs) in the treatment and prevention of cancer |
| Q87400202 | Vulvar cancer and sentinel lymph nodes: a new standard of care? |
| Q92592621 | What can we do to help young cancer survivors minimize financial hardship in the United States? |
| Q92042234 | What can we learn from the association between adolescent alcohol consumption and breast cancer risk? |
| Q84971457 | What is new in kidney cancer? |
| Q37982444 | What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer? |
| Q94605325 | What is the best clinical approach to recurrent/refractory osteosarcoma? |
| Q37085999 | What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941? |
| Q39682966 | What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy? |
| Q99632087 | What is the role of PARP inhibitors in pancreatic cancer? |
| Q39433991 | What is the role of informed decision-making? |
| Q92862487 | What therapies are on the horizon for HER2 positive breast cancer? |
| Q59621879 | What’s the (end) point of cancer vaccines? |
| Q59377156 | When adult cancers occur in children |
| Q42964660 | When and how often should PET scans be performed in the management of cervical cancer? |
| Q55059446 | When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs. |
| Q48111239 | When is contralateral mastectomy warranted in unilateral breast cancer? |
| Q90717205 | When is surgery for metastatic melanoma still the most appropriate treatment option? |
| Q31038305 | Where now for anti-EGF receptor therapies in colorectal cancer? |
| Q88340783 | Why do hemangiopericytomas have such high recurrence rates? |
| Q38062021 | Why do targeted agents not work in the adjuvant setting in colon cancer? |
| Q91418664 | Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy? |
| Q90621120 | Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements? |
| Q56963272 | Why is pancreatic adenocarcinoma not screened for earlier? |
| Q57339511 | Why should survivors of childhood renal tumor and others with only one kidney be denied the chance to play contact sports? |
| Q38658549 | Will new drugs change the standard of care for patients with mantle cell lymphoma? |
| Q34734161 | Wilms tumor: progress to date and future considerations |
| Q36381288 | Wilms' tumor: past, present and (possibly) future. |
| Q82262240 | World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients |
| Q34734513 | ZD1839 (IRESSA): a selective EGFR-TK inhibitor |
| Q34969165 | Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma |
| Q35117725 | Zoledronic acid (Zometa®) use in bone disease |
| Q83645722 | Zoledronic acid for adjuvant use in patients with breast cancer |
| Q38096474 | Zoledronic acid in lung cancer with bone metastases: a review |
| Q37909355 | Zoledronic acid: multiplicity of use across the cancer continuum |
| Q35728765 | c-Myc as a therapeutic target in cancer |
| Q78721309 | deCODE generates first 3D image of anticancer drug activity |
| Q37385392 | mTOR inhibitors for hepatocellular cancer: a forward-moving target |
| Q37086022 | mTOR pathway in renal cell carcinoma |
| Q38192078 | miRNA as markers for the diagnostic screening of colon cancer |
| Q38186130 | miRNA expression profiles associated with diagnosis and prognosis in lung cancer |
| Q38633144 | miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance |
| Q93191111 | microRNAs as biomarkers of ovarian cancer |
| Q82678239 | microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma |
| Q33412928 | nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer |
| Q35117749 | von Hippel-Lindau disease: recent advances and therapeutic perspectives. |
| Q44119515 | β-Blockers and metastasis in non-small-cell lung cancer |
| Q38068208 | β-adrenergic-blocking drugs and melanoma: current state of the art. |
| Expert Review of Anticancer Therapy | wikipedia | |
| Expert Review of Anticancer Therapy | wikipedia | |
| Expert Review of Anticancer Therapy | wikipedia | |
| Expert Review of Anticancer Therapy | wikipedia |
Search more.